

1 **Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a**
2 **Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine**
3 **"Patria" (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector**
4 **(NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline**
5 **Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination**

6 Constantino López-Macías^{1*}, Martha Torres², Brenda Armenta-Copca³, Niels H.
7 Wachter⁴, Arturo Galindo-Fraga⁵, Laura Castro-Castrezana⁶, Andrea Alicia Colli-
8 Domínguez⁷, Edgar Cervantes-Trujano⁸, Isabel Erika Rucker-Joerg⁹, Fernando
9 Lozano-Patiño¹⁰, Juan José Rivera-Alcocer¹¹, Abraham Simón-Campos¹², Efrén
10 Alberto Sánchez-Campos¹³, Rafael Aguirre-Rivero¹⁴, Alejandro José Muñiz-
11 Carvajal¹⁵, Luis del Carpio-Orantes¹⁶, Francisco Márquez-Díaz¹⁷, Tania Rivera-
12 Hernández^{1,18}, Alejandro Torres-Flores^{1,19}, Luis Ramírez-Martínez²⁰, Georgina Paz-
13 De la Rosa²⁰, Oscar Rojas-Martínez²⁰, Alejandro Suárez-Martínez²⁰, Gustavo
14 Peralta-Sánchez²⁰, Claudia Carranza², Esmeralda Juárez²¹, Horacio Zamudio-
15 Meza², Laura E. Carreto-Binaghi², Mercedes Viettri², Damaris Romero-Rodríguez²²,
16 Andrea Palencia², David Sarfati-Mizrahi²⁰, Weina Sun²³, Héctor Elías Chagoya-
17 Cortés²⁴, Felipa Castro-Peralta²⁰, Peter Palese²³, Florian Krammer^{23,25,26}, Adolfo
18 García-Sastre^{23,26,27,28,29,30}, and Bernardo Lozano-Dubernard^{20*}

19 ¹Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de
20 Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro
21 Social (IMSS), Ciudad de México (CDMX), México. ²Laboratorio de Inmunobiología
22 de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER)
23 "Ismael Cosío Villegas", CDMX, México. ³ILS Clinical Research, S.C., CDMX,
24 México. ⁴Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital
25 de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, CDMX, México.
26 ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ),
27 CDMX, México. ⁶CAIMED Investigación en Salud, S. A. de C. V., CDMX, México.
28 ⁷Oaxaca Site Management Organization (OSMO) S.C., Oaxaca, México. ⁸Centro de
29 Investigación Clínica Acelerada (CICA), S.C., CDMX, México. ⁹Clinical Research
30 Institute (CRI) S.C., Edo. de México, México. ¹⁰Centro de Investigación Clínica
31 Chapultepec, CDMX, México. ¹¹Unidad de Atención Médica e Investigación en
32 Salud (UNAMIS), Yucatán, México. ¹²Köhler & Milstein Research (K&M) Facultad de
33 Medicina, Universidad Autónoma de Yucatán, Mérida, Yucatán, México. ¹³Centro
34 Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en
35 Yucatán (CEMDEICY) S.C., Yucatán, México. ¹⁴Centro de Investigación Clínica del
36 Pacífico (CICPA), Guerrero, México. ¹⁵Red OSMO, Centro de Investigación y
37 Avances Médicos Especializados (CIAME), Quintana Roo, México. ¹⁶Instituto
38 Veracruzano de Investigación Clínica (IVIC) S.C., Veracruz, México. ¹⁷Hospital de
39 Cardiológica Aguascalientes, Aguascalientes, México. ¹⁸Investigadores por México,
40 Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), CDMX,
41 México. ¹⁹Posgrado en Inmunología, Escuela Nacional de Ciencias Biológicas,

42 Instituto Politécnico Nacional, CDMX, México. ²⁰Laboratorio Avi-Mex S.A. de C.V.,
43 CDMX, México. ²¹Departamento de Investigación en Microbiología, INER “Ismael
44 Cosío Villegas”, CDMX, México. ²²Unidad de Citometría, INER “Ismael Cosío
45 Villegas”, CDMX, México. ²³Department of Microbiology, Icahn School of Medicine
46 at Mount Sinai, New York, NY, USA. ²⁴Consultora Mexstrategy, S.A.S. de C.V.,
47 CDMX, México. ²⁵Center for Vaccine Research and Pandemic Preparedness (C-
48 VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
49 ²⁶Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of
50 Medicine at Mount Sinai, New York, NY, USA. ²⁷Department of Medicine, Division of
51 Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
52 ²⁸Global Health and Emerging Pathogens Institute, Icahn School of Medicine at
53 Mount Sinai, New York, NY, USA. ²⁹The Tisch Cancer Institute, Icahn School of
54 Medicine at Mount Sinai, New York, NY, USA. ³⁰The Icahn Genomics Institute, Icahn
55 School of Medicine at Mount Sinai, New York, NY, USA.

56 *Correspondence: lozano@avimex.com.mx (B. Lozano-Dubernard),
57 constantino.lopez@imss.gob.mx (C. López-Macías)

58 **Abstract**

59 **Background:** The urgent need for safe, effective, and economical coronavirus
60 disease 2019 (COVID-19) vaccines, especially for booster campaigns targeting
61 vulnerable populations, prompted the development of the AVX/COVID-12 vaccine
62 candidate. AVX/COVID-12 is based in a Newcastle disease virus La Sota (NDV-
63 LaSota) recombinant viral vector. This vaccine expresses a stabilized version of the
64 spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
65 specifically the ancestral Wuhan strain. The study aimed to assess its safety,
66 immunogenicity, and potential efficacy as an anti-COVID-19 booster vaccine.

67 **Methods:** In a phase II/III clinical trial conducted from November 9, 2022, to
68 September 11, 2023, a total of 4,056 volunteers were enrolled. Participants received
69 an intramuscular booster dose of either AVX/COVID-12 or AZ/ChAdOx-1-S
70 vaccines. Safety, immunogenicity, and potential efficacy were assessed through
71 various measures, including neutralizing antibody titers, interferon (IFN)- γ -producing
72 CD4+ T cells, and CD8+ T cells. The evaluation also involved immunobridging,
73 utilizing the AZ/ChAdOx-1-S vaccine as an active comparator, and monitoring the
74 incidence of COVID-19 cases.

75 **Findings:** The AVX/COVID-12 vaccine induced neutralizing antibodies against both
76 the ancestral SARS-CoV-2 and the BA.2 and BA.5 Omicron variants. The geometric
77 mean ratio of neutralizing antibody titers between individuals immunized with the
78 AVX/COVID-12 vaccine and those with the AZ/ChAdOx-1-S vaccine at 14 days is
79 0.96, with a confidence interval (CI) of 0.85-1.06. The outcome aligns with the non-
80 inferiority criterion recommended by the World Health Organization (WHO),
81 indicating a lower limit of the CI greater than or equal to 0.67. Induction of IFN- γ

82 producing CD8+ T cells at day 14 post-immunization was exclusively observed in
83 the AVX/COVID-12 group. Finally, a trend suggested a potentially lower incidence
84 of COVID-19 cases in AVX/COVID-12 boosted volunteers compared to AZ/ChAdOx-
85 1-S recipients.

86 **Conclusion:** The AVX/COVID-12 vaccine proved safe, well-tolerated, and
87 immunogenic. AVX/COVID-12 meets the WHO non-inferiority standard compared to
88 AZ/ChAdOx-1-S. These results strongly advocate for AVX/COVID-12 as a viable
89 booster dose, supporting its utilization in the population.

90 **KEYWORDS:** COVID-19 vaccine, Phase II/III clinical trial, Newcastle disease virus
91 LaSota, SARS-CoV-2.

92 **Introduction**

93 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants of
94 concern have caused hundreds of millions of infections and millions of deaths around
95 the globe since 2020 (1).

96 At the beginning of 2021, anti-SARS-CoV-2 vaccination campaigns had been
97 launched in almost 200 countries with more than 13.53 billion doses distributed (2);
98 as of November 2022, emergency use approval has been granted to 50 vaccine
99 candidates (3). These vaccines have shown to be effective in phase III clinical trials
100 and to induce neutralizing antibodies that target the spike protein of SARS-CoV-2
101 among other antigens less studied (4). In addition to the vaccines already in use,
102 many other candidates are in a preclinical or clinical development.

103 Despite the remarkable speed in the development of coronavirus disease 2019
104 (COVID-19) vaccines since 2020, there have been over 6.9 million official deaths
105 from COVID-19 (1) (with estimates based on excess mortality being 3-4 times
106 higher). Moreover, the unequal global distribution of vaccines, particularly impacting
107 low- and middle-income countries (LMICs), underscores the urgency for the
108 continued development of new vaccine platforms to address disparities in
109 distribution. Ensuring a high vaccination rate worldwide is crucial for reducing the
110 likelihood of new variant emergence. Additionally, the administration of periodic
111 booster doses is essential to prevent subsequent waves of COVID-19 and safeguard
112 vulnerable populations, including the elderly, immunocompromised individuals, and
113 those with comorbidities. Consequently, the global vaccine supply remains an urgent
114 issue that requires attention (5).

115 The AVX/COVID-12 vaccine candidate is a Newcastle disease virus LaSota (NDV-
116 LaSota) vector-based vaccine that expresses the HexaPro version (6 prolines that
117 stabilize the prefusion conformation) of the SARS-CoV-2 spike protein (6,7).

118 Among the main advantages offered by the NDV-LaSota vector is the standardized
119 production process in embryonated chicken eggs, easy to develop in existing
120 facilities for the manufacture of influenza vaccines, achieving the production of large

121 numbers of doses in a short time (8). Therefore, this could help to fulfill vaccine
122 demand, particularly in countries with a low immunization rate or incomplete
123 vaccination scheme.

124 The NDV-LaSota vector, expressing the spike protein of the SARS-CoV-2 virus, has
125 demonstrated efficacy in preclinical studies, particularly in mice and hamsters.
126 Following intranasal (IN) immunization in mice, the generation of IgA and IgG2a
127 antibodies, with a response of IFN- γ -producing T cells, was observed. This vector
128 provided complete protection against infection in mice and hamsters, indicated by
129 the absence of viral titers and viral antigen in the lungs of mice and a significant
130 reduction in SARS-CoV-2 shedding in hamsters (8,9).

131 Preclinical trials involving pigs were conducted in Mexico to assess the safety and
132 immunogenicity of the AVX/COVID-12 vaccine when administered via intramuscular
133 (IM) or IN routes. The study revealed robust responses in serum-neutralizing
134 antibodies, with notable reactivity to variants of concern (VOCs) carrying mutations
135 in the spike protein epitopes (10). In a Phase I clinical trial (NCT04871737) with 91
136 volunteers, the vaccine was evaluated with various booster regimens administered
137 through both IM and IN routes, demonstrating significant immunogenicity in both
138 cases. The safety of this vaccine was also confirmed in these studies, establishing
139 the foundation for further clinical development (11).

140 Similar vaccines are undergoing clinical trials, with a live version being tested in the
141 United States (NCT05181709), whereas inactivated vaccines based on the same
142 vector are also in clinical testing, with ongoing trials in Vietnam (Phase I
143 NCT04830800), Thailand (Phase I/II NCT04764422, Phase III TCTR20221026004),
144 and Brazil (Phase I NCT04993209 and Phase II/III NCT05354024). Available reports
145 indicate favorable safety and immunogenicity profiles for these vaccines (12–14).
146 Recently, an inactivated version of this vaccine was authorized for emergency use
147 as a booster for the prevention of severe COVID-19 in Thailand (15).

148 In Phase II clinical trials, the AVX/COVID-12 vaccine underwent assessment through
149 both IM and IN administrations as a booster dose. The study demonstrated safety
150 and immunogenicity via both routes in volunteers who had previously received
151 mRNA, AZ/ChAdOx-1-S, or inactivated virus vaccines or were infected with SARS-
152 CoV-2, all of whom initially exhibited anti-spike IgG titers below 1,200 units (U)/mL
153 in a chemiluminescence test. AVX/COVID-12 IM or IN immunization induced a
154 significant (≥ 2.5 fold) increase in the neutralizing antibody response against SARS-
155 CoV-2 variants of concern by day 14, despite expressing the original Wuhan-1 strain
156 spike protein. Noteworthy elevations in neutralizing antibodies against multiple
157 variants of concern, including Alpha, Beta, Delta, and Omicron (BA.2 and BA.5),
158 were observed when compared to the placebo groups (16).

159 In this phase II/III parallel study, we investigated the safety and immunogenicity of a
160 single intramuscular booster dose of AVX/COVID-12 in healthy adults with a history
161 of prior COVID-19 vaccination and/or SARS-CoV-2 infection. Unlike in the Phase II

162 trial, participants were included irrespective of their initial anti-S antibody levels.
163 Given the pandemic situation during the recruiting period of the trial (Figure 1S),
164 enrolled individuals exhibited a wide range of baseline antibody titers. Additionally,
165 we conducted an active-controlled non-inferiority study (immunobridging) using the
166 AZ/ChAdOx-1-S vaccine as the comparator, as both are vectorized vaccines. The
167 AZ/ChAdOx-1-S vaccine has proven to be safe and effective against SARS-CoV-2
168 infection, demonstrating an effectiveness of 84.3% against asymptomatic SARS-
169 CoV-2 infection and 98.9% against COVID-19 hospitalization (17,18). Moreover, it
170 has become the most widely used vaccine globally, deployed in 185 countries since
171 its approval for emergency use (19). In Mexico, since November 2021, more than
172 79.43 million doses have been administered, covering single-dose, full vaccination,
173 and booster regimens, utilizing both homologous and heterologous systems (20).
174 The characteristics of AZ/ChAdOx-1-S make it a suitable comparator for testing
175 AVX/COVID-12 in a non-inferiority trial.

176 **Material and methods**

177 **Study design**

178 A phase II/III double-blind study (ClinicalTrials.gov #NCT05710783) was conducted
179 to assess the safety, immunogenicity, and post-boosting incidence of SARS-CoV-2
180 infection following a single IM dose of SARS-CoV-2 vaccine (AVX/COVID-12)
181 “Patria”. The primary objective was to establish non-inferiority in the SARS-CoV-2
182 neutralizing antibodies production at day 14 post-administration by comparing it with
183 an active control, the AZ/ChAdOx-1-S vaccine. Randomization involved the
184 administration of a single IM dose of the experimental AVX/COVID-12 vaccine at a
185 concentration of $10^{8.0}$ tissue culture infective dose 50% (TCID_{50%}) per dose and a
186 single IM dose of the AZ/ChAdOx-1-S vaccine at a concentration of 10^{10} viral
187 particles per dose for subsequent non-inferiority analysis.

188 The protocol was formulated by iLS Clinical Research, S.C. in collaboration with the
189 Mexican Institute for Social Security (IMSS) and Laboratorio Avi-Mex, S.A. de C.V.
190 (Avimex®), which was the sponsor. Approval for the study was granted by the
191 Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in
192 Mexico, assigned the number RNEC2022-AVXSARSCoV2VAC005. Ethics approval
193 was obtained from the institutional ethics committee at each research site
194 participating in the study. The research was conducted in complete compliance with
195 Mexican regulations and in accordance with the principles outlined in the Declaration
196 of Helsinki and Good Clinical Practice. Immunological assay samples were
197 processed at the National Institute for Respiratory Diseases (INER) in Mexico City.

198 **Study groups**

199 The study groups comprised adults aged 18 years or older, of both genders, who
200 were in good health and had received at least one dose of an approved SARS-CoV-
201 2 vaccine. Inclusion criteria for the study involved a negative PCR test for SARS-

202 CoV-2 during the screening visit, a negative pregnancy test in women of childbearing
203 potential, a commitment to maintaining adequate prevention measures to avoid
204 infection with SARS-CoV-2 throughout their participation in the study, especially
205 during the first 14 days after the baseline visit. Importantly, there were no restrictions
206 based on the baseline antibody titers for eligibility in the study.

207 The exclusion criteria encompassed hypersensitivity or allergy to any ingredient of
208 the vaccine, a history of severe anaphylactic reactions, fever at the baseline visit,
209 receipt of the last COVID-19 vaccination within the past 4 months, SARS-CoV-2
210 infection within the last month, pregnancy or nursing status, chronic diseases
211 requiring the use of immunosuppressive agents or immune response modulators
212 (e.g., systemic corticosteroids, cyclosporine, rituximab), active chemotherapy
213 treatment for cancer, a history of human immunodeficiency virus (HIV) infection, and
214 chronic renal or liver disease with a recent history of infectious conditions requiring
215 hospitalization or intravenous drug treatment within the year before the baseline visit.

216 The randomization of volunteers was conducted using a computer-based
217 assignment system, ensuring blinding throughout the study. Upon signing the
218 informed consent form, each participant received a patient number, encoding all their
219 information in a pseudo-anonymized manner during data collection and becoming
220 fully anonymized during the analysis. The stratification for subject randomization is
221 as follows: In phase 2 and the immunobridging phase, blocks of 8 were created, with
222 each block randomly assigning 4 subjects to receive the AVX/COVID-12 vaccine
223 and 4 subjects to receive the AZ/ChAdOx-1-S vaccine. In the follow-up safety phase
224 III, blocks of 8 were also created, with all subjects receiving the AVX/COVID-12
225 vaccine.

226 In phase II, participants were enrolled to receive either the AVX/COVID-12 or
227 AZ/ChAdOx-1-S vaccine. During phase III immunobridging, the phase II participants
228 were included, and new participants were enrolled. For the phase II/III safety
229 assessment, volunteers from the phase III immunobridging and phase II participants
230 were included. Additionally, more volunteers were recruited to receive the
231 AVX/COVID-12 vaccine (Figure 1).

232 **Safety**

233 Safety was assessed through active and passive monitoring of adverse events (AEs)
234 in both the AZ/ChAdOx-1-S and AVX/COVID-12 vaccine groups, taking into account
235 their severity and their relationship to the intervention. The study comprised four
236 visits, with the option for additional visits in case of suspected SARS-CoV-2 infection.
237 While all participants completed the same visits, those assigned to different groups
238 (described above and in Figure 1) underwent additional sample collections during
239 visits on days 0, 14, 90, and 180 of the study.

240 The primary endpoints in the phase II/III and the immunobridging aspects of this trial
241 included solicited local and systemic reactions. These reactions were assessed at

242 the time participants entered the study and continued throughout a 6-month follow-
243 up period. Additionally, the study reported the incidence of symptomatic, severe, or
244 fatal cases of COVID-19.

245 The classification of potential AEs and their association with vaccine exposure
246 followed a two-period analysis. The first period included the initial 7 days following
247 vaccination, during which adverse reactions were deemed related to the vaccine
248 components (19). Conversely, reactions occurring after 7 days, typically in response
249 to the development of an immune response, constituted the second analysis period
250 (19).

251 **Sample collection**

252 Venous blood samples were obtained from participants during scheduled site visits
253 for serology tests and cellular response assessments. The samples were collected
254 into two sodium heparin tubes and one separator tube (SST BD vacutainer tubes,
255 Franklin Lakes, NJ, USA) through standard phlebotomy procedures. Following
256 collection, the samples were transported at room temperature to the INER for
257 immediate processing. All blood samples and their products were handled in a
258 biosafety level (BSL)-2 laboratory, employing appropriate personal protective
259 equipment and safety precautions, adhering to processing protocols approved by
260 the Institutional Biosafety Committee. Serum isolation was performed by centrifuging
261 venous blood collected into SST at 2,260 x g for 10 minutes to separate the serum.
262 The resulting serum was carefully extracted from the upper portion of the tube,
263 aliquoted, and then stored at -20 °C until needed.

264 **Peripheral blood mononuclear cell (PBMC) isolation**

265 PBMC were isolated from venous blood collected in sodium heparin tubes (BD
266 vacutainer tubes, Franklin Lakes, NJ, USA). Within four hours of collection, PBMC
267 isolation was conducted by density-gradient sedimentation of whole blood diluted at
268 a 1:2 ratio in Roswell Park Memorial Institute (RPMI) 1640 medium (Lonza, Basel,
269 Switzerland) at room temperature. The diluted blood was layered over an
270 appropriate volume of room-temperature Lymphoprep (Axis-Shield Diagnostics,
271 Dundee, UK). Then, the PBMC were then recovered, cryopreserved in a medium
272 consisting of 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO, USA)
273 and 90% heat-inactivated fetal bovine serum (FBS; GIBCO, California, USA), and
274 stored at -80 °C until use. For T cell assays, the thawing process involved warming
275 frozen cryovials at 37 °C in a water bath, and cells were resuspended in 5 mL of
276 CTS OpTmizer (GIBCO, California, USA). After a wash with OpTmizer, cells were
277 counted using a Neubauer chamber, and the viability was assessed by trypan blue.
278 Cells were resuspended in OpTmizer medium to a density of 4×10^6 cells/mL.

279 The subunit 1 of the spike protein of SARS-CoV-2 (RayBiotech, Peachtree Corners,
280 GA, USA) was selected as the primary antigen due to its display of most
281 immunogenic epitopes of the spike protein. Additionally, it contains the receptor

282 binding domain (RBD) fragment of the virus, which mediates binding to the host
283 receptor angiotensin-converting enzyme 2 (ACE2).

284 **Pseudovirus neutralization assay**

285 The pseudovirus neutralization assay employed pseudovirus particles based on
286 replication-competent vesicular stomatitis virus (VSV)-eGFP-SARS-CoV-2. These
287 particles encoded the spike gene of the ancestral Wuhan-1 strain, as well as
288 Omicron subvariants BA.2 (VSV-SARS-CoV-2 BA.2 clone 1) and BA.5 (VSV-SARS-
289 CoV-2 BA.5 clone 4). The pseudovirus particles were generously provided by Sean
290 Whelan and used in pseudoviral microneutralization assays.

291 Prior to use in the neutralization assay, all sera were heat-inactivated at 56 °C for 30
292 minutes. Vero E6 cells (ATCC CRL-1586, Manassas, VA, USA) were seeded at a
293 density of 1.3×10^4 cells per well in 96-well plates with 100 μ L of complete EMEM
294 (Eagle's minimum essential medium, ATCC, 30-2003 Manassas, VA, USA)
295 supplemented with 10% fetal bovine serum; (FBS; Gibco, Waltham, MA, USA). The
296 cells were then incubated for 24 hours at 37 °C with 5% CO₂, allowing them to reach
297 approximately 85% confluence.

298 The next day, serum samples were diluted in EMEM medium without FBS using a
299 3-fold serial dilution, starting with a 1:60 dilution. These diluted samples were mixed
300 with 100 TCID₅₀ of VSV-SARS-CoV-2 spike pseudoparticles of the ancestral Wuhan-
301 1 strain or Omicron variants. The mixture was incubated for 60 minutes at 37 °C with
302 5% CO₂ to facilitate the neutralization process. Subsequently, each dilution was
303 transferred to a parallel plate containing Vero E6 monolayers and incubated at 37
304 °C with 5% CO₂ for 72 hours.

305 After the incubation period, 3.7% formaldehyde was added to the culture plates and
306 the plates were incubated 30-40 minutes at room-temperature. Then, the
307 formaldehyde was discarded, and the plates were washed twice with phosphate-
308 buffered saline (PBS; Lonza, Basel, Switzerland). The neutralizing activity of each
309 sample was reported as the titer, represented by the reciprocal of dilution, where the
310 cell protection is 50%; to get this value, we considered the last serum dilution at
311 which the wells are non-infected and with this data, the half maximal 50% inhibitory
312 dilution (ID₅₀) was calculated using the Spearman-Kaerber analysis method. This
313 analysis was based on the presence or absence of cellular damage (cytopathic
314 effect). Each sample was tested in duplicate.

315 **Intracellular cytokine staining assay**

316 Cells were costimulated for 16 hours with costimulation anti-human CD28/CD49d
317 (BD Biosciences, San Jose, CA, USA), spike subunit 1 protein at a concentration of
318 5 μ g/mL. Medium served as a negative control, and phytohemagglutinin (PHA; 1
319 mg/mL) as a positive control. Monensin (GolgiStop BD, San José, CA, USA) was
320 added, and the samples were incubated for 4 hours at 37 °C.

321 After stimulation, the samples were washed with PBS (Lonza, Walkersville, MD,
322 USA) and stained with Live/Dead Fixable near 633 or 635nm (Invitrogen, Waltham,
323 MA, USA) (diluted 1:1000) for 15 minutes at room temperature in the dark.
324 Subsequently, cell surface staining was performed using a cocktail of anti-human
325 CD3-Alexa Fluor 700 (Biolegend, San Diego, CA, USA), CD4-PerCP/Cy5.5
326 (Biolegend, San Diego, CA, USA), and CD8-PE/Cy7 (Biolegend, San Diego, CA,
327 USA) antibodies in cell staining buffer (BioLegend, San Diego, CA, USA). The
328 mixture was incubated for 15 minutes at room temperature in the dark, followed by
329 an additional washing step with cell staining buffer.

330 The cells were fixed and permeabilized using Cytotfix/Cytoperm (BD, San Jose, USA)
331 for 20 minutes at room-temperature. After centrifugation, Perm/Wash (BD, New
332 Jersey, USA) was added. Then, intracellular staining was then performed using a
333 cocktail of anti-human IFN- γ -FITC (BD, San Jose, USA), TNF- α APC (Biolegend,
334 San Diego, CA, USA), and IL-2-BV605 (Biolegend, San Diego, CA, USA) antibodies
335 in Perm/Wash solution for 30 minutes at room temperature in the dark. After washing
336 with BD Perm/Wash buffer (BD, San Jose, USA), the cells were resuspended in PBS
337 and kept at 4 °C in the dark until acquisition and analysis. Unstained and
338 fluorescence minus one (FMO) controls were included.

339 Sample acquisition was carried out on a BD Symphony A1 instrument, previously
340 calibrated with standardized Cytometer Setup and Tracking (CST) beads (BD, San
341 Jose, USA) used for daily quality control. Compensation was performed using
342 CompBeads (BD, San Jose, USA). At least 200,000 events of the lymphocyte region
343 in a Forward Scatter (FSC) vs Side Scatter (SSC) plot were acquired per sample.
344 Analysis was conducted using FACSDiva 8.0.3, and gates for identification of SARS-
345 CoV-2 antigen-specific cytokine-producing CD3+, CD4+, or CD8+ T cells were
346 defined using the FMO controls. This study was approved by the Institutional Review
347 Board for Human Subjects Research at INER.

348 **Statistical analysis**

349 We present results encompassing safety, immunogenicity, efficacy, and a sample
350 size determined through statistical hypothesis testing. To outline the study
351 population demographic characteristics, measures of central tendency and
352 dispersion were employed for continuous variables, while proportions were utilized
353 for discrete or categorical variables. Continuous variables underwent analysis using
354 the student's t-test or non-parametric test where specified, and the categorical
355 variables were compared through a chi-square test.

356 Safety analysis involved the AEs comparison in participants vaccinated with
357 AZ/ChAdOx-1-S (control group) and AVX/COVID-12 (experimental group),
358 considering both severity and their relationship to the intervention. The Z-test was
359 employed to compare the proportions of reported adverse effects between treatment
360 groups.

361 Variations in the neutralizing antibody titers and secreted IFN- γ levels were
362 determined. Statistically significant differences in intra-groups in geometric mean
363 neutralization titers between day 0 and day 14, 90, and 180 were analyzed using a
364 paired t-test for the variable on a logarithmic scale, and the differences in IFN- γ
365 production were determined using Wilcoxon signed ranks test. Significance was set
366 at p-values < 0.05. The confidence interval for the non-inferiority criteria was
367 obtained through a student's t-test for the variable on a logarithmic scale.

368 The analysis of the incidence of symptomatic, severe, or fatal cases of COVID-19 is
369 described by Nelson Alen's cumulative hazard rate, and the difference between
370 groups was evaluated with a log rank test.

371 The statistical analysis was performed with STATA v 17.0 (StataCorp, College
372 Station, TX, USA).

373 **Results**

374 **Randomization of study participants**

375 From November 9, 2022, to September 11, 2023, a total of 4,201 volunteers
376 underwent eligibility assessments, and 134 subjects were excluded due to failure to
377 meet eligibility criteria. The distribution of recruited volunteers is depicted in Figure
378 1. Various research sites across different states of Mexico participated in volunteer
379 recruitment, including Aguascalientes (Hospital Cardiológica Aguascalientes),
380 Guerrero (CICPA Centro de Investigación Clínica del Pacífico), Mexico City
381 (CAIMED Investigación en Salud, S.A. de C.V., Centro de Investigación Clínica
382 Chapultepec, CICA Centro de Investigación Clínica Acelerada, S.C., INCMNSZ
383 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Unidad de
384 Medicina Familiar No. 20 IMSS), Michoacán (Sociedad Administradora de Servicios
385 de Salud, S.C.), Oaxaca (OSMO Oaxaca Site Management Organization S.C.),
386 Quintana Roo (Red OSMO Centro de Investigación y Avances Médicos
387 Especializados), State of Mexico (CRI Clinical Research Institute S.C.), Veracruz
388 (Instituto Veracruzano de Investigación Clínica S.C.), and Yucatán (Centro
389 Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en
390 Yucatán (CEMDEICY) S.C.P., K&M Köhler & Milstein Facultad de Medicina,
391 Universidad Autónoma de Yucatán, Mérida, Unidad de Atención Médica e
392 Investigación en Salud (UNAMIS)).

393 A total of 4,067 participants were initially randomized for the study, with 11
394 withdrawing consent post-randomization, and 4,056 were vaccinated. In phase II,
395 422 participants were enrolled, with 218 receiving the AVX/COVID-12 vaccine and
396 204 administered the AZ/ChAdOx-1-S vaccine. In phase III immunobridging, 1,417
397 participants were enrolled, including 705 who received the AVX/COVID-12 vaccine
398 and 712 who received the AZ/ChAdOx-1-S vaccine. For phase II, 44 AVX/COVID-
399 12 and 36 AZ/ChAdOx-1-S vaccinees dropped out, leaving 174 AVX/COVID-12 and
400 168 AZ/ChAdOx-1-S participants who completed the study. In phase III

401 immunobridging, 143 AVX/COVID-12 and 127 AZ/ChAdOx-1-S vaccinees dropped
402 out, leaving 562 AVX/COVID-12 and 585 AZ/ChAdOx-1-S participants who
403 completed the study. For phase II/III safety, 4,056 participants were enrolled, 3,120
404 received AVX/COVID-12. In addition, 936 volunteers were vaccinated with
405 AZ/ChAdOx-1-S. 225 dropouts were recorded from the AVX/COVID-12 group and
406 127 from the AZ/ChAdOx-1-S group (Figure 1).

407 For the groups vaccinated with AVX/COVID-12 and AZ/ChAdOx-1-S, the average
408 age was 39 years. No statistically significant differences were observed between the
409 groups in terms of age, sex, race, or comorbidities, suggesting that both groups are
410 comparable concerning these variables (Table 1).

411 Information regarding prior SARS-CoV-2 infection and vaccination history was
412 collected from participants in the immunobridging study (Table 2). Results show no
413 statistically significant difference in the average time since the last infection and that
414 the proportion of subjects with a history of SARS-CoV-2 infection is the same for
415 both groups. Similarly, the proportion of subjects vaccinated with different vaccine
416 technologies is comparable, considering the number of doses received.

417 **Safety after boosting with AVX/COVID-12**

418 Out of the total population evaluated for safety (n=4,056 subjects), 2,111 vaccinated
419 subjects reported adverse events during the study. Among them, 51.37% of the
420 subjects in the AVX/COVID-12 group (n=1,603) and 54.27% in the AZ/ChAdOx-1-S
421 group (n=508) experienced adverse events, showing no statistically significant
422 differences among the groups (Figure 2A). When categorizing events by severity
423 (mild, moderate, or severe), it was observed that for mild events, a higher proportion
424 of subjects were affected in the AZ/ChAdOx-1-S group compared to the
425 AVX/COVID-12 vaccine group (p=0.02). Conversely, for moderate adverse events,
426 the proportion was higher in individuals who received the AVX/COVID-12 vaccine
427 (p=0.01). Finally, for severe adverse events, no statistically significant differences
428 were observed between the two groups (Figure 2A).

429 In the context of local adverse events of special interest, 800 volunteers (25.64%)
430 were documented in the AVX/COVID-12 vaccinated group, while 193 volunteers
431 (20.61%) were recorded in the AZ/ChAdOx-1-S vaccinated group. This indicates a
432 statistically significant difference (p=0.002), with a higher incidence observed in the
433 AVX/COVID-12 group compared to the AZ/ChAdOx-1-S group. Regarding
434 musculoskeletal and connective tissue disorders, nervous system disorders, and
435 skin and subcutaneous tissue disorders, there were no statistically significant
436 differences observed between the two groups (Figure 2B). The analyzed disorders
437 include musculoskeletal and connective tissue issues (arthralgia, myalgia, back
438 pain, pain in a limb, and limb discomfort), local general disorders (heat, pain, edema,
439 redness, hematoma, swelling, induration, inflammation, nerve injury, itching at the
440 injection site) nervous system disorders (paresthesia) and skin and subcutaneous
441 tissue disorders (erythema, papule, and itching) (Table 1S).

442 For systemic AEs of special interest within 7 days post-vaccination, statistically
443 significant differences were observed only in cases of mild severity. Specifically, 496
444 cases (15.89%) were reported in volunteers from the AVX/COVID-12 group,
445 compared to 183 cases (19.55%) from the AZ/ChAdOx-1-S group ($p=0.008$) (Table
446 S2). Importantly, there was a statistically significant difference in general disorders
447 and administration site alterations in favor of the AVX/COVID-12 group ($p=0.0008$)
448 (Figure 2C). The analyzed disorders include vascular (flushing, hypertensive crisis,
449 and hypotension), respiratory, thoracic, and mediastinal (asthma, nasal congestion,
450 dyspnea, pharyngolaryngeal pain, hiccups, allergic rhinitis, rhinorrhea, cough, and
451 productive cough), and psychiatric (mood changes, confusional state, insomnia, and
452 irritability), ocular (allergic conjunctivitis and photopsia), musculoskeletal and
453 connective tissue (arthralgia, back pain, myalgia, ligament sprain, muscle spasms,
454 and discomfort in limbs), systemic general disorders, and administration site
455 alterations (asthenia, chest pain, influenza-like illness, shivering, fatigue, peripheral
456 coldness, hyperthermia, inflammation, discomfort, general discomfort, chest
457 tightness, pyrexia, decreased thirst, and feeling cold), gastrointestinal (diarrhea,
458 abdominal distension, abdominal pain, upper abdominal pain, constipation, nausea,
459 odynophagia, vomiting, and aphthous ulcer), and nervous system (headache,
460 dizziness, migraine, paresthesia, drowsiness, and tremor), immune system
461 (hypersensitivity), ear and labyrinth (vertigo), metabolism and nutrition (decreased
462 appetite), reproductive and breast (polymenorrhea, heavy menstrual bleeding, and
463 menstrual disorders), skin and subcutaneous tissue (rash, excessive sweating, skin
464 lesions, and hives), cardiac (chest pain, palpitations, and tachycardia), and
465 infections (oral herpes) (Table 2S).

466 Regarding participants who experienced AEs potentially associated with the
467 vaccine, a total of 539 volunteers (17.27%) from AVX/COVID-12 and 122 from
468 AZ/ChAdOx-1-S (13.03%) were reported. Significant differences ($p=0.01$) were
469 observed in general disorders and administration site alterations (asthenia, pain at
470 the injection site, edema at the injection site, erythema at the injection site, chill,
471 fatigue, hematoma at the injection site, swelling, induration at the injection site,
472 inflammation at the injection site, nerve injury at the injection site, discomfort, general
473 discomfort, fever, and decreased thirst), predominantly occurring in volunteers
474 vaccinated with AVX/COVID-12 (Figure 2D). No statistical differences were
475 observed in the other analyzed disorders (Figure 2D).

476 **AVX/COVID-12 booster-induced neutralizing antibody titers against Wuhan-1** 477 **strain and Omicron SARS-CoV-2 variants of concern**

478 The evaluation of neutralizing antibody titers in sera from AVX/COVID-12 boosted
479 volunteers against the spike protein was conducted using the pseudovirus
480 neutralization assay at 0, 14, 90, and 180 days post-immunization. Following the
481 booster with AVX/COVID-12, anti-SARS-CoV-2 antibody titers against the ancestral
482 Wuhan-1 strain or Omicron (BA.2 and BA.5) variants of concern were induced.
483 Specifically, titers against the ancestral Wuhan-1 variant significantly increased at

484 day 14 and slightly declined at day 90 and 180 post-immunization. In contrast, for
485 the BA.2 and BA.5 variants, significantly higher neutralizing titers were observed at
486 days 14, 90, and 180 after boosting (Figure 3A).

487 The pattern of neutralizing titers remained consistent for BA.2 and BA.5 variants,
488 depicting an increase at days 14 and 90, followed by a decline at day 180 post-
489 boosting (Figure 3A). Notably, neutralizing antibody titers against the BA.2 and BA.5
490 variants were 1 to 3 times lower than those observed against the ancestral Wuhan-
491 1 strain. Despite the decrease in titers at day 180, it is important to highlight that
492 these titers against the BA.2 and BA.5 variants remained significantly higher
493 compared to baseline levels before boosting with the AVX/COVID-12 vaccine.

494 As part of exploratory objectives, the magnitude of the increase in neutralizing titers
495 at 0, 14, 90, and 180 days, following the administration of the AVX/COVID-12
496 vaccine in a single IM booster dose regimen, was analyzed. This analysis was
497 stratified based on the immunization/infection history at the time of recruitment
498 (Figure 3B). The data consistently demonstrate significantly increased titers at day
499 14 across all subgroups. However, following this time point, titers tended to decrease
500 in all four subgroups. Based on this analysis, no differences were noted among the
501 subgroups following the administration of the AVX/COVID-12 vaccine booster
502 (Figure 3B). Here, “homologous boost” indicates using the same vaccine platform as
503 the primary series, whereas “heterologous boost” refers to employing a different
504 vaccine platform for the primary series. Analysis of the groups was conducted
505 irrespective of their prior infection status (Figure 3B)

506 The neutralizing antibody titers following AVX/COVID-12 and AZ/ChAdOx-1-S
507 boosting were evaluated across participants with comorbidities and different age
508 groups. The antibody titers at day 0 and day 14 indicated that both vaccines induced
509 similar enhancements in neutralizing antibody titers among participants with
510 comorbidities and those aged > 65 and < 65 years (Figure 2S).

511 **Phase III immunobridging**

512 **Similar neutralizing antibody responses after booster doses of AVX/COVID-12** 513 **or AZ/ChAdOx-1-S vaccines**

514 The non-inferiority of AVX/COVID-12, in comparison to the AZ/ChAdOx-1-S vaccine,
515 was evaluated in 705 volunteers who received the AVX/COVID-12 booster and 712
516 who received the AZ/ChAdOx-1-S booster. Both groups were comparable, showing
517 no statistical differences in age, gender, or race. However, there were statistically
518 significant differences observed in individuals with obesity and normal body mass
519 index (BMI), as well as those with 0 or 1 comorbidities. Nevertheless, no differences
520 were noted among underweight and overweight volunteers or individuals with 1, 2,
521 and 3 or more comorbidities (Table 3). Additionally, there were no statistically
522 significant differences in volunteers based on their prior infection or vaccination
523 history (Table 4).

524 The assessment of the non-inferiority of the AVX/COVID-12 vaccine, compared to
525 the AZ/ChAdOx-1-S vaccine, was conducted by calculating the confidence interval
526 for the ratio of geometric means of neutralizing titers and the confidence interval for
527 the difference in the proportion of subjects with seroconversion, following the WHO
528 guidelines for non-inferiority vaccine studies (19).

529 The analysis of the anti-Wuhan-1 strain neutralizing titers revealed well-balanced
530 baseline values for the overall subject sample ($p=0.23$) (Table 5). The geometric
531 mean ratio between those immunized with the AVX/COVID-12 vaccine and those
532 with the AZ/ChAdOx-1-S vaccine at 14 days is 0.96, with a confidence interval of
533 0.85-1.06 (Table 5), demonstrating that AVX/COVID-12 is non-inferior to
534 AZ/ChAdOx-1-S (Figure 4A). This result aligns with the non-inferiority criterion
535 recommended by the WHO, indicating a lower limit of the confidence interval greater
536 than or equal to 0.67 (21).

537 Upon further analysis of the neutralizing response, when stratifying boosted
538 volunteers into seroconverted and non-seroconverted groups, it was found that
539 58.15% of subjects in the AVX/COVID-12 vaccinated group seroconverted, while in
540 the AZ/ChAdOx-1-S vaccinated group, the proportion was 55.75%. The
541 AVX/COVID-12 vaccinated group maintains a 2.4% advantage over the
542 AZ/ChAdOx-1-S vaccinated group, with a confidence interval (CI) of -2.7 to 7.5. This
543 outcome is consistent with the protocol non-inferiority criterion, indicating that the
544 difference in both percentages should not exceed -10 (21). Notably, individuals in
545 both vaccine groups who experienced seroconversion exhibited an approximately
546 fourfold increase in their neutralizing titers 14 days after immunization. Conversely,
547 the group that did not undergo seroconversion showed a decline in neutralizing titers
548 at day 14 after boost for both vaccines (Figure 4B). This group was characterized by
549 individuals with high titers of neutralizing antibodies prior to the vaccination boost,
550 and these titers still remained high after the observed decline and day 14 after the
551 boost (Figure 4B)

552 **T-cell responses among participants immunized with AVX/COVID-12 or** 553 **AZ/ChAdOx-1-S vaccines.**

554 The production of IFN- γ by peripheral blood total, CD4+, and CD8+ T cells in
555 response to stimulation with the subunit 1 of the spike protein of SARS-CoV-2 was
556 assessed on days 0, 14, 90, and 180 in PBMCs from volunteers who received
557 booster doses of AVX/COVID-12 (Figure 5A) or AZ/ChAdOx-1-S (Figure 5B), using
558 flow cytometry.

559 In subjects vaccinated with AVX/COVID-12, a slight increase in total T cells and
560 CD4+ T cells producing IFN- γ was observed on day 14; however, this rise did not
561 reach statistical significance. Nevertheless, a notable increase in the percentage of
562 IFN- γ -producing CD8+ T cells ($p=0.006$) was detected on day 14 compared to the
563 baseline levels on day 0 (Figure 5A and Table 3S). Statistically significant decreases

564 were observed in total IFN- γ -producing T cells only at day 180. In the case of the
565 IFN- γ -producing CD4+ T cells, a decrease was noted at day 90 with no further
566 decrease. For IFN- γ -producing CD8+ T cells, the reduction was observed only at
567 day 180 (Figure 5A and Table 3S).

568 For volunteers immunized with AZ/ChAdOx-1-S, no significant increases were noted
569 in total CD4+ and CD8+ IFN- γ -producing T cells (Figure 5B and Table 3S).
570 Statistically significant decreases in IFN- γ -producing T cells were observed only at
571 days 90 and 180. In the case of the IFN- γ -producing CD4+ T cells, the decrease
572 occurred at day 14, with no further drop observed. Finally, a reduction in IFN- γ -
573 producing CD8+ T cells was observed at day 90, with no subsequent change (Figure
574 5B and Table 3S). In Figure 5, statistically significant increases are depicted in black,
575 and decreases are shown in red.

576 **Similar incidence of COVID-19 cases in volunteers boosted with AVX/COVID- 577 12 or AZ/ChAdOx-1-S vaccines**

578 As part of the secondary objectives for phase III, the occurrence of symptomatic
579 COVID-19 cases was documented for both the AVX/COVID-12 and AZ/ChAdOx-1-
580 S groups of boosted volunteers during the 14 days following administration. A total
581 of 37 COVID-19 cases (5.5%) were recorded in the AVX/COVID-12 boosted group,
582 and 42 cases were reported in the AZ/ChAdOx-1-S group (6.3%), resulting in an
583 incidence rate per 1000 days of 0.29 and 0.32 for AVX/COVID-12 and AZ/ChAdOx-
584 1-S, respectively (Table 6). Despite the trial not being designed for efficacy analysis,
585 the log rank test indicated no significant difference in the cumulative incidence of
586 COVID-19 cases between both groups ($p=0.42$) (Table 6). Additionally, a
587 comparison of Nelson-Aalen cumulative hazard incidence curves for COVID-19
588 cases reported during the 180 days after boosting with AVX/COVID-12 or
589 AZ/ChAdOx-1-S showed no statistically significant differences between volunteers
590 vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S (Figure 6).

591 **Discussion**

592 The naturally attenuated lentogenic NDV LaSota strain is an avian virus that exhibits
593 host-range restriction, thereby preventing productive multicycle infection in non-
594 avian species, including humans. As a live vaccine vector, it has been employed in
595 the veterinary industry for over 70 years, demonstrating a commendable track record
596 of safety and efficacy (22). NDV-vectored vaccines have undergone preclinical
597 studies against various coronaviruses, revealing their safety and immunogenicity in
598 natural poultry host and non-natural mammalian challenge models (23–25). The
599 natural attenuation of NDV confers an advantage over other live viral vaccines used
600 in humans, as it is unlikely to induce disease in humans or any wild or domestic avian
601 species. Studies have indicated that the introduction of foreign genes into NDV
602 genomes results in reduced pathogenicity in birds, rather than an increase (26).
603 Consequently, the NDV-based AVX/COVID-12 does not pose any discernible

604 environmental or agricultural risks (27). Of note, the inserted HexaPro spike protein
605 is non-functional since its fusion machinery has been disabled by the introduction of
606 the prolines and by removing the cleavage site between spike subunit 1 and spike
607 subunit 2.

608 The safety of the AVX/COVID-12 vaccine, administered via IM or IN routes, was
609 initially confirmed through preclinical tests conducted in pigs (10). This confirmation
610 was validated in a phase I clinical trial involving volunteers with no prior history of
611 infection or vaccination (28). Considering that a significant portion of the population
612 had previously encountered infection or received vaccination at the time of the study,
613 a subsequent phase II clinical trial was conducted to assess the safety and
614 immunogenicity of the AVX/COVID-12 vaccine as a heterologous booster dose
615 through both IM and IN routes. The trial demonstrated that the vaccine retained its
616 safety and immunogenicity when employed as a booster dose (16). Reports from
617 clinical trials involving COVID-19 NDV-based vaccines similar to AVX/COVID-12
618 also indicate that these vaccines are safe and well tolerated in humans (12–15).

619 In this study, we further analyzed the safety and immunogenicity of the AVX/COVID-
620 12 vaccine as an IM booster in healthy adult volunteers who have gone more than
621 four months since their last COVID-19 vaccination and/or SARS-CoV-2 infection.
622 Additionally, a non-inferiority study was conducted using the AZ/ChAdOx-1-S
623 vaccine as an active control. The safety, immunogenicity, and efficacy of the
624 intranasal administration of the AVX/COVID-12 vaccine will be investigated in future
625 studies.

626 The assessment of AEs and their potential association with vaccination was
627 conducted in 4,056 subjects over a six-month period. Of these, 3,120 received a
628 single IM dose of the AVX/COVID-12 vaccine, while 936 received the AZ/ChAdOx-
629 1-S vaccine as an active control. While the use of a placebo during the phase II
630 stages facilitates a clear definition of the immune response magnitude in subjects
631 receiving the experimental vaccine, incorporating placebo controls in pharmaceutical
632 development protocols for COVID-19 vaccines, at the time of this trial, presented an
633 ethical conflict as vaccines with emergency authorization and national vaccination
634 plans became available. Consequently, placebo controls were not employed in this
635 study. Instead, AZ/ChAdOx-1-S as active control was utilized during phase II to
636 prevent bias in subject distribution and serve as a comparator for assessing the
637 vaccine's safety. On the other hand, during the phase III stage, the active control
638 was employed to accurately define biologically relevant non-inferiority and avoid a
639 potential bio-creep effect (29).

640 The primary vaccine-associated AEs in the phase II-III study were predominantly
641 mild and associated with the administration site. Few severe AEs were reported, no
642 statistically significant differences were observed between the two groups, and they
643 were not related to vaccination. However, regarding the statistically significant
644 differences, it was found that general reactions and pain at the injection site were

645 more frequent in the AVX/COVID-12 group than in the AZ/ChAdOx-1-S group.
646 Nevertheless, systemic events were more frequent in the case of the AZ/ChAdOx-
647 1-S group. It is important to emphasize that there were no statistical differences in
648 adverse events between the entire population vaccinated with AZ/ChAdOx-1-S or
649 AVX/COVID-12 (Figure 2A). Furthermore, the nature, incidence, and severity of
650 adverse events recorded during this study do not indicate any alarming signals
651 following the administration of the AVX/COVID-12 vaccine. The demonstrated safety
652 of the AVX/COVID-12 vaccine aligns with the outcomes of earlier clinical phases
653 (11,16).

654 The findings outlined in this report highlight the immunogenicity of the vaccine,
655 evidenced by an increase in neutralizing antibody titers, not only against the
656 ancestral Wuhan-1 strain but also against the Omicron BA.2 and BA.5 variants of
657 concern (Figure 3). While the neutralizing antibody responses showed an initial
658 increase at day 14 followed by a gradual decline, it is noteworthy that even after 6
659 months, antibody titers remained higher compared to pre-boosting levels (Figure 3).
660 This persistence aligns with observations reported for other COVID-19 vaccines
661 (30).

662 Furthermore, the analysis of the geometric mean ratio (GMT) of neutralizing
663 antibodies demonstrated that the AVX/COVID-12 experimental vaccine (GMT ratio:
664 0.96, CI: 0.85-1.06) met the standard set by the WHO (GMT \geq 0.67) (Table 5) (21),
665 confirming its non-inferiority when compared to the AZ/ChAdOx-1-S vaccine.

666 The efficacy of the AZ/ChAdOx-1-S vaccine had been previously established in
667 clinical studies with placebo controls (31). Moreover, primary-series AZ/ChAdOx-1-
668 S vaccination protects against COVID-19 hospitalization with enduring levels of
669 vaccine effectiveness through \geq 6 months, as indicated by consistent results in a
670 meta-regression analysis. The analysis showed \geq 80% protection against COVID-19
671 hospitalization through approximately 43 weeks post-second dose, with a certain
672 decline (17,18). This vaccine was the most widely used in vaccination campaigns in
673 Mexico and is the most utilized globally, distributed in 185 countries (2,17).
674 Therefore, it serves as an excellent active control for the non-inferiority study of the
675 AVX/COVID-12 vaccine.

676 Further data analysis indicates that a percentage of individuals in both groups did
677 not seroconvert. Approximately 40% of those vaccinated with both AVX/COVID-12
678 and AZ/ChadOx-1-S did not seroconvert when measuring response against the
679 ancestral Wuhan-1 strain, while it was 20% when considering those who did not
680 seroconvert in response to Wuhan, BA.2, and BA.5 (triple negatives). In other words,
681 60% seroconverted when measuring the response against the Wuhan-1 strain, and
682 around 80% seroconverted when considering the response measured against
683 Wuhan-1 or the BA.2 or BA.5 Omicron strains. This trend was observed in both the
684 AVX/COVID-12 and AZ/ChadOx-1-S vaccinated groups (Figure 4B).

685 The lack of seroconversion has been reported both in some infected patients (32)
686 and vaccinated individuals (33), particularly in patients with prior infection, where
687 seroconversion after receiving a vaccine booster is much lower or non-existent when
688 neutralizing titers are high due to previous infections (33). In this study, 32% of the
689 volunteers exhibited anti-N titers (data not shown), indicating prior infection (or
690 vaccination with inactivated vaccines). Additionally, the study was conducted during
691 a pandemic peak caused by the Omicron variant (Figure 1S), leading to around 40%
692 of participants having titers of 1,024 and above at baseline (Figure 4B). The analysis,
693 comparing baseline titers and the percentage of seroconversion, clearly shows that
694 higher baseline titers are associated with lower seroconversion, aligning with existing
695 literature (33).

696 In the case of volunteers who did not seroconvert in both the AVX/COVID-12 and
697 AZ/ChadOx-1-S boosted groups, it was interestingly observed that the antibody titers
698 were declining at day 14 (Figure 4B). Further analysis revealed that these volunteers
699 had very high baseline titers. This phenomenon has been previously reported in
700 similar cases (33,34), especially in volunteers with high baseline titers receiving
701 homologous boosters. Additionally, studies in mice have shown that immunization
702 schemes involving multiple doses lead to a reduced response of neutralizing
703 antibodies, with a diminished T-cell response, decreased formation of germinal
704 centers, and cellular response exhaustion (35). This information could contribute to
705 explaining the observed response in the study patients. It is also crucial to consider
706 that most of these volunteers had already developed robust hybrid immunity due to
707 previous vaccinations and infections. Furthermore, the study was conducted during
708 a peak of Omicron infections (Figure 1S), and undetected exposure to the virus could
709 have contributed to the observed response. These data indicate that in individuals
710 with high neutralizing antibody titers, the boosting does not improve the response;
711 on the contrary, it could not prevent waning in antibody titers. This information is
712 relevant for planning and deploying vaccination campaigns to maximize the benefits
713 of vaccination.

714 Nevertheless, the analysis of the volunteers' neutralizing antibody responses
715 confirmed that the AVX/COVID-12 vaccine meets the WHO non-inferiority standard
716 compared to the AZ/ChAdOx-1-S vaccine. Individuals with baseline neutralization
717 titers around 400, boosted either with AVX/COVID-12 or AZ/ChAdOx-1-S, exhibited
718 a 3 to 4-fold increase in seroconversion for both groups (Figure 4A and 4B). These
719 results underscore the effectiveness and importance of timely boosting in specific
720 individuals. It is important to note that this trial included participants regardless of
721 their initial anti-S IgG titers. The seroconversion observed in volunteers with initially
722 low antibody titers aligns with phase II clinical trial findings, where participants had
723 similarly low anti-S IgG titers at the beginning of the study (16). Notably, this phase
724 II/III study demonstrates that boosting individuals with high neutralizing antibody
725 titers does not result in a further increase; in fact, it might not stop antibody waning,
726 though this decline does not reach initial levels as high antibody titers persist.

727 The primary focus of anti-COVID-19 boosting campaigns is on the elderly,
728 immunocompromised, and individuals with comorbidities. Upon further examination
729 of neutralizing antibody titers following AVX/COVID-12 or AZ/ChAdOx-1-S boosting,
730 both vaccines exhibited comparable enhancements in neutralizing antibody titers
731 among participants with comorbidities, as well as those aged > 65 and < 65 years
732 (Figure 2S). This data supports the use of these vaccines as boosters in these
733 populations. Further studies are required to evaluate the safety and immunogenicity
734 of this vaccine in immunocompromised individuals, pregnant women and kids.

735 With time, the combination of infection and vaccination generates hybrid immunity,
736 which has been demonstrated to broaden and enhance the neutralizing antibody
737 and T-cell responses, providing increased protection against infection,
738 hospitalization, and death (36). This report illustrates the induction of a neutralizing
739 response against the Omicron variant of concern (VOC) through boosting with
740 AVX/COVID-12 or AZ/ChAdOx-1-S. Since both vaccines express the spike protein
741 of the ancestral Wuhan-1 strain, the anti-Omicron neutralizing response may be
742 attributed to extensively documented cross-reactivity. This phenomenon is
743 particularly evident in the context of hybrid immunity, which has been shown to
744 broaden and enhance the response of neutralizing antibodies, not only against the
745 ancestral variant but also against new variants and other seasonal coronaviruses as
746 well as SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS
747 CoV) (33). Given the pandemic status when the trial was conducted, the induction
748 of antibodies against variants other than Wuhan-1 is not surprising, considering the
749 large number of T and B cell epitopes shared by the spike proteins from SARS-CoV-
750 2 variants of concern (37).

751 Regarding the cellular response, an increase in the total CD4+ and CD8+ T cell
752 responses was observed on day 14 after receiving the booster dose. However, the
753 increase was statistically significant only for CD8+ cells producing IFN- γ . It is
754 important to note that the data suggest that at the initiation of this study, the
755 proportions of IFN- γ -producing T lymphocytes were relatively high in the participating
756 subjects, as there is a trend indicating a significant decrease at days 90 and 180.
757 This trend is also observed for subjects enrolled in the group that received the
758 AZ/ChAdOx-1-S vaccine, suggesting that, at a population level, due to the active
759 circulation of the virus, there were initially high baseline levels of T lymphocytes
760 specific to the SARS-CoV-2 spike protein. While it was possible to detect significant
761 increases in the specific cellular response to the virus, the high baseline levels
762 prevented clearer observations of cellular response increases (Figure S1).
763 Considering the inclusion criteria, which allowed the recruitment of individuals
764 vaccinated or previously infected with SARS-CoV-2 for four months or more, it is
765 anticipated that the cellular response would already be elevated (30). This makes it
766 challenging to observe a distinct increase after the booster. Reports from 2022
767 estimated that at least 51% of the population had hybrid immunity, with 85%
768 exhibiting some level of Omicron-induced antibody titers (38). Additional studies

769 propose limited potential for further boosting, notably in individuals initially primed
770 with infection followed by three mRNA vaccine doses, which maximally induce spike-
771 specific T-cell responses (39). This report also illustrates that a previous history of
772 SARS-CoV-2 infection can modify immune responses to the spike protein during
773 Omicron infection in vaccinated populations. Nevertheless, Omicron infection in
774 individuals who have received triple vaccinations generally heightens immune
775 responses to SARS-CoV-2 in both the bloodstream and mucosal regions. This
776 enhancement potentially fortifies long-lasting population immunity against SARS-
777 CoV-2 (39). Other studies have indicated that vaccination with BNT162b2, based on
778 the Wuhan-1 spike protein, and/or breakthrough infection by early Omicron
779 subvariants elicits CD8+ T cell responses that recognize epitopes within the spike
780 protein of newly emerging subvariants (40).

781 Collectively, these findings suggest that hybrid immunity acquired from both
782 vaccination and past infections can prompt notably heightened and broader immune
783 responses. This combined immunity shows the potential to offer protection against
784 emerging variants of concern.

785 The evaluation of COVID-19 cases among recipients of AVX/COVID-12 or
786 AZ/ChAdOx-1-S vaccines revealed no cases of severe disease, with only mild to
787 moderate disease observed in both groups. An analysis conducted 14 days post-
788 vaccination indicated a trend towards a lower occurrence of COVID-19 cases in
789 individuals boosted with AVX/COVID-12 in comparison to the AZ/ChAdOx-1-S
790 vaccine group, despite the trial not being designed for efficacy analysis.

791 The urgent need persists for the development of safe, effective, and cost-efficient
792 vaccines against COVID-19, especially for implementing booster campaigns aimed
793 at vulnerable groups like the elderly, immunocompromised individuals, and those
794 with comorbidities. This also serves the crucial goal of limiting transmission among
795 the wider population. The results presented here collectively support the utilization
796 of the AVX/COVID-12 vaccine to address this pressing need.

797 **Conclusions**

798 Our findings demonstrate that the AVX/COVID-12 vaccine is safe, well-tolerated,
799 and highly immunogenic. It effectively stimulated the production of neutralizing
800 antibodies against the spike protein from both the ancestral Wuhan-1 strain and the
801 Omicron variants BA.2 and BA.5. Additionally, at day 14 post-immunization,
802 AVX/COVID-12 uniquely induced IFN- γ -producing CD8+ T cells. Furthermore, a
803 discernible trend indicated a potentially lower incidence of COVID-19 cases among
804 volunteers who received the AVX/COVID-12 booster compared to those who
805 received the AZ/ChAdOx-1-S vaccine, supporting the conclusion of non-inferiority.
806 Consequently, the AVX/COVID-12 vaccine meets the WHO's non-inferiority
807 standard when compared to AZ/ChAdOx-1-S. These compelling findings strongly
808 advocate for the incorporation of the AVX/COVID-12 vaccine as a booster dose for
809 the general population.

810 **Acknowledgments**

811 From CONAHCYT, we acknowledge María Elena Álvarez-Buylla Rocés and Delia
812 Aideé Orozco Hernández for their role as an inter-institutional liaison and overall
813 facilitation of proceedings, committee evaluations, sanitary setup, and follow-up of
814 trial design approvals, evaluations, and progress. We additionally acknowledge the
815 broader support from various teams within all the clinical research sites and iLS
816 Clinical Research S.C., particularly Gabriela Rosas, Daniela Castro, Claudia Aguilar,
817 Roman Jarosch, and Alejandro Arias. From Laboratorio Avi-Mex, S. A. de C. V., we
818 acknowledge the following people for their operative support: Bernardo Lozano
819 Alcántara, Alejandro Ruiz, Rosalba Rodríguez, Leticia Espinosa Gervasio, Rodrigo
820 Yebra Reyes, Vanessa Escamilla Jiménez, Jaime Becerra Jiménez, Lorena Juárez
821 Pedraza, Sandra Yuridia Ang Tinajero, Avelia Ariadna Cuevas Cifuentes, Juan
822 Pablo Robles Álvarez, Avirán Almazán Gutiérrez, Aurora Betsabé Gutiérrez
823 Balderas, Merlenne Rubio Díaz, and Guadalupe Aguilar Rafael. From INER, we
824 acknowledge the following people for their technical support: Liliana Figueroa
825 Hernández, Francisco Cruz Flores, Claudia Ivett Hernández Lazaro, María Angelica
826 Velázquez González, Jessica Romero Rodríguez, Dulce Cinthia Soriano
827 Hernández, Milton Nieto Ponce, Edgar Reyna, Itzel Corona, José E. Marquez,
828 Angelica Moncada, and Pablo Franco-Mendoza. From IMSS, we acknowledge the
829 help of Diego Lozano-Cisneros in formatting the manuscript. From the Icahn School
830 of Medicine at Mount Sinai, we acknowledge Sean Whelan. From Instituto
831 Politécnico Nacional, Escuela Nacional de Ciencias Biológicas, we acknowledge
832 Sonia Mayra Pérez Tapia, Alexis Gabriel Suárez Gómez, and Sandra Comparan
833 Alarcón.

834 **Funding:** The funding for the clinical study was provided by the National Council for
835 Humanities, Science and Technology (CONAHCYT, México), except for all the
836 production and vaccine product supply, which was funded solely by Laboratorio Avi-
837 Mex, S. A. de C. V. (Avimex). CONAHCYT did not participate in the trial design but
838 did evaluate it and approved the project through their National Committee for
839 Science, Technology and Innovation in Public Health. Funding was managed by
840 Avimex and used to pay for all laboratory tests, clinical sites, and clinical
841 professionals. CONAHCYT also facilitated the identification, purchase, and
842 importation of certain supplies and the communication with other entities of the
843 Federal Mexican Government to facilitate the study.

844 **Conflict of Interest:** The vaccine candidate administered in this study was
845 developed by faculty members at the Icahn School of Medicine at Mount Sinai
846 including P.P., F.K. and A.G.-S. Mount Sinai is seeking to commercialize this
847 vaccine; therefore, the institution and its faculty inventors could benefit financially.
848 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to
849 SARS-CoV-2 serological assays (USA Provisional Application Numbers:
850 62/994,252, 63/018,457, 63/020,503, and 63/024,436) and NDV-based SARS-CoV-
851 2 vaccines (USA Provisional Application Number: 63/251,020) which list FK as co-

852 inventor. A.G.-S. and P.P. are a co-inventor in the NDV-based SARS-CoV-2 vaccine
853 patent application. Patent applications were submitted by the Icahn School of
854 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market
855 serological tests for SARS-CoV-2 and another company, CastleVax, to
856 commercialize SARS-CoV-2 vaccines. F.K., P.P. and A.G.-S. serve on the scientific
857 advisory board of CastleVax and are listed as co-founders of the company. F.K. has
858 consulted for Merck, Seqirus, Curevac, and Pfizer, and is currently consulting for
859 Gritstone, Third Rock Ventures, GSK, and Avimex. The F.K. laboratory has been
860 collaborating with Pfizer on animal models of SARS-CoV-2. C.L.-M. has consulted
861 for AstraZeneca. The A.G.-S. laboratory has received research support from GSK,
862 Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex,
863 Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius,
864 Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied
865 Biological Laboratories and Merck. A.G.-S. has consulting agreements for the
866 following companies involving cash and/or stock: Amovir, Vivaldi Biosciences,
867 Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied
868 Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary,
869 Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in
870 meeting events organized by Seqirus, Janssen, Abbott, and AstraZeneca. P.P. has
871 a consulting agreement with Avimex.

872 Members of Avimex developed the live vaccine used in this study. Avimex filed
873 patent applications with Mount Sinai and CONAHCYT. M.T., D.S.-M., C.L.-M.,
874 H.E.C.-C., F.C.-P., G.P.D.L., and B.L.-D. are named as inventors on at least one of
875 those patent applications. The clinical study was entirely performed in Mexico and
876 Mount Sinai had no role in the clinical study. The rest of the participants are
877 employees of their corresponding institutions and declare no competing interests.

878 **Ethical Responsibilities:** The protocol was approved by the ethics, research, and
879 biosafety committees of each clinical research site, National Committee for Science,
880 Technology and Innovation in Public Health of the National Council for Humanities,
881 Science, and Technology (CONAHCYT), and also by the Federal Commission for
882 the Protection against Sanitary Risks (COFEPRIS, Mexico) as a regulatory agency.

883 **Protection of Humans and Animals:** No animals were used in this study. The
884 protocol was designed to comply with the ethical principles of the Helsinki
885 Declaration, Good Clinical Practices, and the applicable Mexican law.

886 **Data Confidentiality and Sharing:** The protocol was registered in the National
887 Registry of Clinical Studies under number RNEC2022-AVXSARSCoV2VAC005 and
888 published under NCT05710783. Individual de-identified participant data will not be
889 shared beyond the limits permitted by the informed consent and Mexican law.
890 Specifically, this includes the sharing of the study protocol, statistical analysis plan,
891 informed consent form, and approved clinical study report. Additionally, other de-
892 identified data allowed under the informed consent and Mexican law may be shared.

893 The data will be made available immediately upon publication and for 12 months
894 thereafter. Access to the data will be granted solely to investigators with
895 methodologically sound proposals, subject to authorization by an independent
896 review committee and the ethics committees involved in approving the protocol. If
897 required by law, authorization from the Federal Commission for the Protection
898 against Sanitary Risks (COFEPRIS) in Mexico will also be obtained. Any use of the
899 data must strictly adhere to the authorized purposes outlined during the approval
900 process.

901 **Privacy Rights and Informed Consent:** Informed Consent formats were provided
902 and signed by all participants under Good Clinical Practices and Mexican law.
903 Personal data is confidential, and subjects are not identified personally. Their data
904 was analyzed and duly de-identified.

905 **References**

- 906 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19)
907 Dashboard With Vaccination Data [Internet]. [cited 2023 Jan 5]. Available
908 from: <https://covid19.who.int/>
- 909 2. Coronavirus Pandemic (COVID-19) - Our World in Data [Internet]. [cited
910 2023 Nov 15]. Available from: <https://ourworldindata.org/coronavirus>
- 911 3. COVID19 Vaccine Tracker [Internet]. [cited 2023 Nov 15]. Available from:
912 <https://covid19.trackvaccines.org/>
- 913 4. Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and safety of
914 covid-19 vaccines in phase iii trials: A meta-analysis. *Vaccines* [Internet].
915 2021 Jun 1 [cited 2023 Nov 15];9(6). Available from:
916 </pmc/articles/PMC8228087/>
- 917 5. Global Dashboard for Vaccine Equity - UNDP Data Futures Platform
918 [Internet]. [cited 2023 Jan 5]. Available from: [https://data.undp.org/vaccine-](https://data.undp.org/vaccine-equity/)
919 [equity/](https://data.undp.org/vaccine-equity/)
- 920 6. Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S,
921 Lertjintanakit S, et al. Mice immunized with the vaccine candidate hexapro
922 spike produce neutralizing antibodies against sars-cov-2. *Vaccines*.
923 2021;9(5):1–9.
- 924 7. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K,
925 et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes.
926 *Science* [Internet]. 2020 Sep 1 [cited 2023 Nov 15];369(6510):1501–5.
927 Available from: <https://pubmed.ncbi.nlm.nih.gov/32703906/>
- 928 8. Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamaniq
929 S, et al. A Newcastle disease virus expressing a stabilized spike protein of
930 SARS-CoV-2 induces protective immune responses. *Nat Commun* 2021 121
931 [Internet]. 2021 Oct 27 [cited 2023 Jan 5];12(1):1–14. Available from:
932 <https://www.nature.com/articles/s41467-021-26499-y>

- 933 9. Park JG, Oladunni FS, Rohaim MA, Whittingham-Dowd J, Tollitt J, Hodges
934 MDJ, et al. Immunogenicity and protective efficacy of an intranasal live-
935 attenuated vaccine against SARS-CoV-2. *iScience* [Internet].
936 2021;24(9):102941. Available from:
937 <https://doi.org/10.1016/j.isci.2021.102941>
- 938 10. Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez
939 L, Quezada-Monroy F, et al. Safety and Immunogenicity of a Newcastle
940 Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-
941 12-HEXAPRO (Patria), in Pigs. *MBio* [Internet]. 2021 Oct 1 [cited 2023 Jan
942 5];12(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/34544278/>
- 943 11. Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
944 P, Carranza-Salazar DE, et al. Interim safety and immunogenicity results
945 from an NDV-based COVID-19 vaccine phase I trial in Mexico. *npj Vaccines*
946 [Internet]. 2023;8(1):67. Available from: [https://doi.org/10.1038/s41541-023-](https://doi.org/10.1038/s41541-023-00662-6)
947 [00662-6](https://doi.org/10.1038/s41541-023-00662-6)
- 948 12. Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc
949 Dang M, et al. Safety and immunogenicity of an egg-based inactivated
950 Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim
951 results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
952 *Vaccine* [Internet]. 2022 Jun 9 [cited 2023 Nov 15];40(26):3621–32. Available
953 from: <https://pubmed.ncbi.nlm.nih.gov/35577631/>
- 954 13. Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul
955 S, Sivakorn C, et al. Safety and immunogenicity of an inactivated
956 recombinant Newcastle disease virus vaccine expressing SARS-CoV-2
957 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
958 *EClinicalMedicine* [Internet]. 2022 Mar 1 [cited 2023 Nov 15];45. Available
959 from: <https://pubmed.ncbi.nlm.nih.gov/35284808/>
- 960 14. Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul
961 S, Sivakorn C, et al. Safety and Immunogenicity of an Inactivated
962 Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2
963 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2
964 Trial. *medRxiv* [Internet]. 2021 Sep 22 [cited 2023 Nov
965 15];2021.09.17.21263758. Available from:
966 <https://www.medrxiv.org/content/10.1101/2021.09.17.21263758v2>
- 967 15. องค์การเภสัชกรรม (อภ.) the Government Pharmaceutical Organization (GPO)
968 Thailand [Internet]. [cited 2024 Jan 29]. Available from:
969 <https://www.gpo.or.th/view/1029>
- 970 16. Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, Niels
971 Wachter, Laura Castro-Castrezana, Andrea Alicia Colli-Domínguez, Tania
972 Rivera-Hernández, Alejandro Torres-Flores, Luis Ramírez-Martínez,
973 Georgina Paz-De la Rosa, Oscar Rojas and BL-D. A Phase II Study
974 Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-

- 975 Controlled Randomized Phase, Assessing Single-Dose Intramuscular or
976 Intranasal Administration to Evaluate the Safety and Immunogenicity of the
977 Recombinant Vaccine Against. Manuscr Submitt medRxiv. 2024;
- 978 17. Abdel-Qader DH, Abdel-Qader H, Silverthorne J, Kongkaew C, Meslamani
979 AZA, Hayajneh W, et al. Real-World Effectiveness of Four Types of COVID-
980 19 Vaccines. *Vaccines* [Internet]. 2023 May 1 [cited 2023 Nov 15];11(5).
981 Available from: <https://pubmed.ncbi.nlm.nih.gov/37243089/>
- 982 18. Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C,
983 Ouwens M, et al. Protection against COVID-19 hospitalisation conferred by
984 primary-series vaccination with AZD1222 in non-boosted individuals: first
985 vaccine effectiveness results of the European COVIDRIVE study and meta-
986 regression analysis. *Lancet Reg Heal - Eur*. 2023 Aug 1;31:100675.
- 987 19. Covid World Vaccination Tracker - The New York Times [Internet]. [cited
988 2023 Nov 15]. Available from:
989 [https://www.nytimes.com/interactive/2021/world/covid-vaccinations-](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html)
990 [tracker.html](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html)
- 991 20. COVID-19: dosis confirmadas de vacunas en México 2021 | Statista
992 [Internet]. [cited 2023 Nov 15]. Available from:
993 [https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-](https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-covid-mexico/)
994 [covid-mexico/](https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-covid-mexico/)
- 995 21. Guidelines on clinical evaluation of vaccines: regulatory expectations, Annex
996 1 , TRS No 924 [Internet]. [cited 2023 Nov 15]. Available from:
997 [https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-](https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations)
998 [vaccines-regulatory-expectations](https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations)
- 999 22. Samal SK. Newcastle disease virus. *Avian Virol Res Futur Trends*, 1st ed;
1000 Samal, SK, Ed. 2019;43–85.
- 1001 23. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, et
1002 al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector
1003 for intranasal immunization against emerging pathogens. *Proc Natl Acad Sci*
1004 *U S A* [Internet]. 2007 Jun 5 [cited 2023 Nov 15];104(23):9788–93. Available
1005 from: <https://pubmed.ncbi.nlm.nih.gov/17535926/>
- 1006 24. LIU R qiang, GE J ying, WANG J ling, SHAO Y, ZHANG H lei, WANG J
1007 liang, et al. Newcastle disease virus-based MERS-CoV candidate vaccine
1008 elicits high-level and lasting neutralizing antibodies in Bactrian camels. *J*
1009 *Integr Agric JIA* [Internet]. 2017 Oct 1 [cited 2023 Nov 15];16(10):2264–73.
1010 Available from: <https://pubmed.ncbi.nlm.nih.gov/32288953/>
- 1011 25. Shirvani E, Paldurai A, Manoharan VK, Varghese BP, Samal SK. A
1012 Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of
1013 Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. *Sci*
1014 *Rep* [Internet]. 2018 Dec 1 [cited 2023 Nov 15];8(1). Available from:
1015 <https://pubmed.ncbi.nlm.nih.gov/30097608/>

- 1016 26. Park M-S, Steel J, García-Sastre A, Swayne D, Palese P. Engineered viral
1017 vaccine constructs with dual specificity: Avian influenza and Newcastle
1018 disease. *Proc Natl Acad Sci [Internet]*. 2006 May 23;103(21):8203–8.
1019 Available from: <https://doi.org/10.1073/pnas.0602566103>
- 1020 27. Shirvani E, Samal SK. Newcastle Disease Virus as a Vaccine Vector for
1021 SARS-CoV-2. *Pathog (Basel, Switzerland) [Internet]*. 2020 Aug 1 [cited 2023
1022 Nov 15];9(8):1–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32751194/>
- 1023 28. Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
1024 P, Carranza-Salazar DE, et al. Safety and immunogenicity of a live
1025 recombinant Newcastle disease virus-based COVID-19 vaccine (Patria)
1026 administered via the intramuscular or intranasal route: Interim results of a
1027 non-randomized open label phase I trial in Mexico. *medRxiv [Internet]*. 2022
1028 Feb 9 [cited 2023 Nov 15];7–127. Available from:
1029 </pmc/articles/PMC8845421/>
- 1030 29. Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials.
1031 *Stat Med [Internet]*. 2010 Nov [cited 2023 Nov 15];29(27):2769–80. Available
1032 from: <https://pubmed.ncbi.nlm.nih.gov/20809482/>
- 1033 30. Guerrera G, Picozza M, D’Orso S, Placido R, Pirronello M, Verdiani A, et al.
1034 BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a
1035 stem cell memory phenotype. *Sci Immunol [Internet]*. 2023 Jul
1036 12;6(66):eab15344. Available from:
1037 <https://doi.org/10.1126/sciimmunol.ab15344>
- 1038 31. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et
1039 al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
1040 SARS-CoV-2: an interim analysis of four randomised controlled trials in
1041 Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99–111.
- 1042 32. Figueiredo-Campos P, Blankenhau B, Mota C, Gomes A, Serrano M, Ariotti
1043 S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19
1044 patients and healthy volunteers up to 6 months post disease onset. *Eur J
1045 Immunol [Internet]*. 2020 Dec 1 [cited 2023 Nov 15];50(12):2025–40.
1046 Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048970>
- 1047 33. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
1048 Immunogenicity of standard and extended dosing intervals of BNT162b2
1049 mRNA vaccine. *Cell [Internet]*. 2021 Nov 11 [cited 2023 Nov
1050 15];184(23):5699-5714.e11. Available from:
1051 <https://pubmed.ncbi.nlm.nih.gov/34735795/>
- 1052 34. Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos
1053 Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19
1054 booster vaccination in previous recipients of two doses of CoronaVac
1055 COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single
1056 blind, randomised study. *Lancet (London, England) [Internet]*. 2022 Feb 5
1057 [cited 2023 Nov 15];399(10324):521–9. Available from:

- 1058 <https://pubmed.ncbi.nlm.nih.gov/35074136/>
- 1059 35. Gao FX, Wu RX, Shen MY, Huang JJ, Li TT, Hu C, et al. Extended SARS-
1060 CoV-2 RBD booster vaccination induces humoral and cellular immune
1061 tolerance in mice. *iScience* [Internet]. 2022 Dec 22 [cited 2023 Nov
1062 15];25(12):105479. Available from:
1063 <http://www.cell.com/article/S2589004222017515/fulltext>
- 1064 36. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM,
1065 et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron
1066 Infections. *N Engl J Med* [Internet]. 2022 Jul 7 [cited 2023 Nov
1067 15];387(1):21–34. Available from:
1068 <https://pubmed.ncbi.nlm.nih.gov/35704396/>
- 1069 37. Pacheco-Olvera DL, Saint Remy-Hernández S, García-Valeriano MG,
1070 Rivera-Hernández T, López-Macías C. Bioinformatic Analysis of B- and T-
1071 cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential
1072 Cross-reactivity with Emerging Variants and other Human Coronaviruses.
1073 *Arch Med Res* [Internet]. 2022 Nov 1 [cited 2024 Jan 19];53(7):694–710.
1074 Available from: <https://pubmed.ncbi.nlm.nih.gov/36336501/>
- 1075 38. Frei A, Kaufmann M, Amati R, Dettwiler AB, Wyl V von, Annoni AM, et al.
1076 Development of hybrid immunity during a period of high incidence of
1077 infections with Omicron subvariants: A prospective population based multi-
1078 region cohort study. *medRxiv* [Internet]. 2022 Oct 17 [cited 2023 Nov
1079 15];2022.10.14.22281076. Available from:
1080 <https://www.medrxiv.org/content/10.1101/2022.10.14.22281076v1>
- 1081 39. Hornsby H, Nicols AR, Longet S, Liu C, Tomic A, Angyal A, et al. Omicron
1082 infection following vaccination enhances a broad spectrum of immune
1083 responses dependent on infection history. *Nat Commun* 2023 141 [Internet].
1084 2023 Aug 21 [cited 2023 Nov 15];14(1):1–16. Available from:
1085 <https://www.nature.com/articles/s41467-023-40592-4>
- 1086 40. Kim SH, Kim J, Jung S, Noh JY, Kim J, Park H, et al. Omicron BA.2
1087 breakthrough infection elicits CD8+ T cell responses recognizing the spike of
1088 later Omicron subvariants. *Sci Immunol*. 2024;9(91):eade6132.
- 1089




Figure 1. Participant Screening and Randomization. A flowchart illustrating the screening, randomization, and distribution of participants among different experimental groups throughout the study.




Figure 2. Local and systemic adverse events 7 days after boosting with AVX/COVID-12 or ChAdOx-1-S. Compilation of clinical data and adverse events in participants following boosting with AVX/COVID-12 or ChAdOx-1-S vaccines. A) Percentage of participants affected by adverse events classified by severity; B) participants affected by local adverse events of special interest; C) participants affected by systemic adverse events of special interest, and D) participants affected by adverse events with a confirmed relation to the vaccine according to the investigator's criteria. The analyzed disorders are listed in supplementary tables 1 and 2. p-values were calculated through a comparison of proportions using the Z-test. Statistically significant differences were observed with p-values: $p \leq 0.05$.




Figure 3. AVX/COVID-12 boosting induced neutralizing antibody titers against ancestral Wuhan-1 and Omicron SARS-CoV-2 variants of concern. Assessment of neutralizing antibody titers in sera from AVX/COVID-12 boosted volunteers against the S protein using the pseudovirus neutralization assay. A) Anti- SARS-CoV-2 antibody titers against Wuhan-1 or Omicron (BA.2 and BA.5) variants of concern. B) Specific neutralizing antibody titers against Wuhan-1 strain in participants with different history of immunization and infection induced by AVX/COVID-12 vaccine boost. Homologous boost refers to the use of the same vaccine platform used for the primary series vaccination; heterologous boost refers to the use a different vaccine platform used for the primary series vaccination. ± Infection groups includes infected and non-infected participants. The limit of detection is 60, although it is not specified in the graph. Dots represent the geometric mean, while bars indicate the 95% confidence intervals for the error. The p-values from the statistical analysis are presented in bold numbers, where $p > 0.05$ is considered statistically significant. A paired t-test was employed to compare neutralizing titers.




Figure 4. Similar neutralizing antibody responses were observed in participants who received booster doses of AVX/COVID-12 or AZ/ChAdOx-1-S. Analysis of neutralizing antibody titers against Wuhan-1 strain in participants boosted with AVX/COVID-12

(red circles) or AZ/ChAdOX-1-S (gray squares): A) Antibody titers in all boosted subjects on days 0 and 14 and B) comparison between participants who seroconverted (closed symbols) and subjects who did not seroconverted (open symbols). No statistically significant differences were observed, with $p > 0.05$ considered as the threshold for statistical significance.




Figure 5: T cell responses in participants vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S vaccines. A) Percentage of IFN- γ -producing total, CD4+ and CD8+ T cells from peripheral blood mononuclear cells collected from participants who received booster doses of AVX/COVID-12 or B) AZ/ChAdOx-1-S vaccines. The cells were stimulated with the subunit 1 of spike protein, and the production of IFN- γ was assessed using flow cytometry. The limit of detection (LoD) of the % IFN- γ producing total T cells is 0.006, % IFN- γ producing CD4+ T cells is 0.006 and % IFN- γ producing CD8+ T cells is 0.006. The graph shows individual value. Bars shows geometric Mean, and the error shows the 95% confidence intervals. Statistically significant increases are depicted in black; this was observed only in IFN- γ -producing T cells from participants vaccinated with AVX/COVID-12. Statistically significant differences with decreases are shown in red. p-values: $p \leq 0.05$ for intragroup comparisons using the Wilcoxon Friedman signed-rank test.






Figure 6. The incidence of COVID-19 cases showed no statistically significant difference between the participants vaccinated with AVX/COVID-12 or AZ/ChAdOx-1-S. Comparison of Nelson-Aalen cumulative hazard incidence curves for COVID-19 cases reported during the 180 days after boosting with AVX/COVID-12 or AZ/ChAdOx-1-S.



Supplementary Figure 1. COVID-19 incidence in Mexico during the recruitment and monitoring of the study participants.



Supplementary Figure 2. AVX/COVID-12 and AZ/ChAdOx-1-S Boosting Elicited Comparable Increases in Neutralizing Antibody Titers Among Participants with Comorbidities, as well as in Subjects >65 and <65 Years Old. The geometric mean and confidence interval for antibody titers at day 0 and day 14 are displayed for AVX/COVID-12 (red circles) and AZ/ChAdOx-1-S (gray squares). Both vaccines exhibited comparable rises in neutralizing antibody titers among participants with comorbidities and in those aged >65 and <65 years old.

Tables

Table 1. Phase II/III demographic characteristics

n (%)	AVX 3120	AZ 936
Age, mean (SD)	39.8 (15.2)	39.6 (14.6)
Age groups		
< 20 years old	116 (3.7)	43 (4.5)
20 - 29 years old	903 (28.9)	264 (28.2)
30 - 39 years old	622 (19.9)	180 (19.2)
40 - 49 years old	612 (19.6)	189 (20.1)
50 - 59 years old	496 (15.9)	163 (17.4)
60 - 69 years old	260 (8.3)	78 (8.3)
70 - 79 years old	97 (3.1)	16 (1.7)
80 and more	14 (0.4)	3 (0.3)
Gender, n (%)		
Male	1430 (45.8)	440 (47)
Female	1690 (54.2)	496 (53)
BMI, mean (SD)	28 (5.3)	28.6 (5.5)
BMI classification		
Underweight	32 (1)	9 (1)
Normal	966 (31)	228 (24.4)
Overweight	1168 (37.4)	370 (39.5)
Obesity	954 (30.5)	329 (35)
Race, n (%)		
Amerindian	24 (0.77)	16 (1.7)
White	157 (5)	73 (7.8)
Mexican Mestizo	2928 (93.8)	836 (89.3)
Other	11 (0.35)	11 (1.1)
Comorbidities, n (%)		
0	2665 (85.4)	781 (83.4)
1	361 (11.6)	128 (13.7)
2	94 (3)	27 (2.9)
3 or more	9 (0.28)	7 (0.74)
Asthma	36 (1.15)	12 (1.3)
Systolic arterial hypertension	297 (9.5)	104 (11.1)
Type 2 Diabetes Mellitus	216 (6.9)	66 (7.1)

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation, BMI = Body Mass Index.

Table 2. History of prior SARS-CoV-2 vaccination and/or infection of the phase II/III participants at baseline

n (%)	AVX	AZ
-------	-----	----

	3120	936
Prior infection, n (%)	191 (6.1)	53 (5.6)
Time (months) since last infection, mean (SD)	14.2 (10.8)	12.2 (10.9)
Number of prior vaccines, n (%)		
1	1103 (35.35)	313 (33.44)
2	1324 (42.44)	394 (42.09)
3	600 (19.23)	211 (22.54)
4	87 (2.79)	18 (1.92)
5	6 (0.19)	0
Previous vaccination dose(s) received, n (%)		
AstraZeneca		
1	914 (29.29)	252 (26.92)
2	754 (24.17)	236 (25.21)
3 or more	146 (4.68)	53 (5.66)
Pfizer		
1	133 (4.26)	45 (4.81)
2	458 (14.68)	126 (13.46)
3	12 (0.38)	5 (0.53)
CanSino		
1	411 (13.17)	172 (18.38)
2	52 (1.67)	10 (1.07)
3	1 (.03)	0
Sputnik		
1	196 (6.28)	50 (5.34)
2	186 (5.96)	44 (4.70)
3	43 (1.38)	9 (0.96)
Sinovac		
1	81 (2.60)	28 (2.99)
2	148 (4.74)	34 (3.63)
3	3 (0.10)	0
Moderna		
1	78 (2.50)	34 (3.63)
2	38 (1.22)	9 (0.96)
3	2 (0.06)	0
Novavax		
1	7 (0.22)	5 (0.53)
2	10 (0.32)	3 (0.32)
3	35 (1.12)	22 (2.35)
Coronavac		
1	8 (0.26)	0
2	20 (0.64)	3 (0.32)
Janssen		
1	14 (0.45)	5 (0.53)

n (%)	AVX 3120	AZ 936
2	12 (0.38)	5 (0.53)
Sinopharm		
1	2 (0.06)	0
Curevac		
1	0	0
2	0	2 (0.21)

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation.

Table 3. Demographic characteristics of phase III immunobridging

n (%)	AVX 705 (49.7)	AZ 712 (50.3)	p-Value
Age, mean (SD)	40.3 (14.8)	40.3 (14.5)	0.81
Age groups			
< 20 years old	25 (3.5)	28 (3.9)	0.61
20 – 29 years old	195 (27.6)	191 (26.8)	
30 - 39 years old	134 (19)	135 (18.9)	
40 - 49 years old	152 (21.5)	149 (20.9)	
50 – 59 years old	111 (15.7)	137 (19.2)	
60 - 69 years old	67 (9.5)	59 (8.2)	
70 – 79 years old	18 (2.5)	11 (1.5)	
80 and more	3 (0.4)	2 (0.2)	
Gender, n (%)			
Male	330 (46.8)	341 (47.9)	0.68
Female	375 (53.2)	371 (52.1)	
BMI, mean (SD)	27.9 (5.1)	28.8 (5.5)	0.002
BMI classification			
Underweight	5 (0.7)	7 (1)	0.008
Normal	214 (30.3)	162 (22.7)	
Overweight	271 (38.4)	285 (40)	
Obesity	215 (30.5)	258 (36.2)	
Race, n (%)			
Amerindian	13 (1.8)	14 (1.9)	0.71
White	39 (5.5)	50 (7)	
Mexican Mestizo	643 (91.2)	638 (89.6)	
Other	10 (1.4)	10 (1.4)	
Comorbidities, n (%)			
0	433 (61.4)	380 (53.3)	0.01
1	216 (30.6)	249 (34.9)	
2	43 (6.1)	65 (9.13)	

3 or more	13 (1.8)	18 (2.5)	
Asthma	7 (1.0)	8 (1.1)	0.81
Systolic arterial hypertension	59 (8.3)	83 (11.6)	0.04
Type 2 Diabetes Mellitus	41 (5.8)	56 (7.8)	0.12

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation, BMI = Body Mass Index. Mann–Whitney U tests were conducted for the comparison for continuous variables, and the Chi-Square test for categorical variables. In instances where a p-value is not displayed, it indicates that the sample size was inadequate to conduct the analysis. Statistically significant differences indicated by p-values: $p \leq 0.05$.

Table 4. History of prior SARS-CoV-2 vaccination and/or infection of participants of the phase III immunobridging study at baseline

n (%)	AVX 705 (49.8)	AZ 712 (50.2)	p-Value
Prior infection, n (%)	33 (4.6)	38 (5.3)	0.57
Time (month) since last infection, mean (SD)	13.7 (7.3)	16 (8.7)	0.28
Number of prior vaccines, n (%)			
1	218 (30.92)	233 (32.72)	0.73
2	306 (43.40)	294 (41.29)	
3	169 (23.97)	169 (23.73)	
4	12 (1.70)	16 (2.24)	
Previous vaccination dose(s) received, n (%)			
AstraZeneca			
1	182 (25.81)	178 (25)	0.84
2	171 (24.25)	182 (25.56)	
3 or more	45 (6.38)	45 (6.32)	
Pfizer			
1	29 (4.11)	31 (4.35)	0.85
2	96 (13.61)	93 (13.06)	
3	3 (0.42)	2 (0.28)	
Cansino			
1	118 (16.73)	124 (17.41)	0.24
2	12 (1.70)	7 (0.98)	
Sputnik			
1	47 (6.66)	50 (7.02)	0.4
2	42 (5.95)	38 (5.33)	
3	13 (1.84)	8 (1.12)	
Sinovac			
1	15 (2.12)	24 (3.37)	0.25
2	28 (3.97)	28 (3.93)	
3	1 (0.14)	0	
Moderna			

n (%)	AVX	AZ	p-Value
	705 (49.8)	712 (50.2)	
1	32 (4.53)	23 (3.23)	0.12
2	4 (0.56)	9 (1.26)	
Novavax			
1	2 (0.28)	4 (0.56)	0.62
2	4 (0.56)	3 (0.42)	
3	11 (1.56)	18 (2.52)	
Coronavac			
1	3 (0.42)	0	0.99
2	8 (1.13)	3 (0.42)	
Janssen			
1	2 (0.28)	3 (0.42)	0.99
2	3 (0.42)	3 (0.42)	
Curevac			
1	0	0	
2	0	2 (0.28)	NA

Note: AVX = Vaccine AVX/COVID-12, AZ = Vaccine ChAdOx-1-S, SD = Standard Deviation. Mann–Whitney U tests were conducted for the comparison for continuous variables, and the Chi-Square test for categorical variables. In instances where a p-value is not displayed (NA), it indicates that the sample size was inadequate to conduct the analysis. Statistically significant differences indicated by p-values: $p \leq 0.05$.

Table 5. AVX/COVID-12 vaccine meets WHO's non-inferiority criteria in comparison to AZ/ChAdOx-1-S neutralizing antibody titers at 14 days post-boosting

	Basal		GM Ratio	P-Value
	AVX/COVID-12	AZ/ChAdOx-1-S		
TOTAL Subjects	705	712		
GM of neutralizing antibody titers	767.5	836.5	0.92	0.23
CI	690.8 - 852.7	760.7 - 919.9	0.78 - 1.03	
Seroconverted participants				
GM	410	397	0.84	0.05
CI	409.5	487.9	0.70 - 1.00	
CI	359.9 - 465.9	433.3 - 549.3		
Non-seroconverted participants				
GM	295	315	1.11	0.20
CI	1837.6	1650.3	0.94 - 1.31	
CI	1631.5 - 2069.7	1467.3 - 1856.1		
14 días				
	AVX	AZ	GM Ratio	
TOTAL Subjects	705	712		
GM	1305.2	1364.38	0.96	
CI	1210.8 - 1407.5	1260.7- 1476.5	0.85 - 1.06	
Seroconverted participants	410	397		

GM	1484.5	1763.1	0.84
CI	1342.8 -1641.1	1587.9 - 1957.6	0.72 - 0.97
Non-seroconverted participants			
	295	315	
GM	1091.5	987.6	1.11
CI	977.2 - 1219.2	883.8 -1103.6	0.94 - 1.29

Note: GM = Geometric Mean, CI = Confidence Interval, The GM ratio was calculated as GM AVX/COVID-12 / GM AZ/ChAdOx-1-S. The CIs were calculated using a t-Student test with the transforming variable on a natural logarithmic scale.

Table 6. Incidence of COVID-19 cases

Subjects in the study	Total 1,417	AVX/COVID-12 705 (49.8)	AZ/ChAdOx-1-S 712 (50.2)
Total follow-up time in days	255,143	127,120	128,023
Average time (SD) in days	180 (31.6)	180.3 (29.6)	179.8 (33.5)
COVID-19 cases (%) ¹	79 (5.5)	37 (5.3)	42 (6.3)
Incidence rate per 1000 days	0.30	0.29	0.32

¹Log Rank Test: p-value = 0.58

Supplementary Table 1. Proportion of affected subjects by local adverse events of special interest at 7 days post-immunization

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value	
Subjects			3120		936		4056			
Any AE		Total	800	(25.64)	193	(20.61)	993	(24.48)	0.001	
		Mi	698	(22.37)	173	(18.48)	871	(21.47)	0.01	
		Mo	108	(3.46)	21	(2.24)	129	(3.18)	0.06	
		S	9	(0.28)	0	(0)	9	(0.22)	0.10	
Skin and subcutaneous tissue disorders		Total	23	(0.73)	5	(0.53)	28	(0.69)	0.51	
		Mi	17	(0.54)	5	(0.53)	22	(0.54)	0.96	
		Mo	6	(0.19)	0	(0)	6	(0.14)	0.17	
		S	0	(0)	0	(0)	0	(0)		
	Erythema	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58	
	Papule	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67	
	Itching	Mi	15	(0.48)	4	(0.42)	19	(0.46)	0.83	
	Itching	Mo	5	(0.16)	0	(0)	5	(0.12)	0.22	
Nervous system disorders		Total	6	(0.19)	0	(0)	6	(0.14)	0.17	
		Mi	5	(0.16)	0	(0)	5	(0.12)	0.22	
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58	
		S	0	(0)	0	(0)	0	(0)		
	Paresthesia	Mi	5	(0.16)	0	(0)	5	(0.12)	0.22	
	Paresthesia	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58	
General disorders and local events		Total	786	(25.19)	190	(20.29)	976	(24.06)	0.002	
		Mi	685	(21.95)	170	(18.16)	855	(21.07)	0.01	
		Mo	101	(3.23)	21	(2.24)	122	(3)	0.11	
		S	9	(0.28)	0	(0)	9	(0.22)	0.10	
		Heat at the vaccination site	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
		Pain at the application site	Mi	3	(0.09)	0	(0)	3	(0.07)	0.34
	Pain at the application site	Mi	655	(20.99)	165	(17.62)	820	(20.21)	0.02	

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	Pain at the injection site	Mo	98	(3.14)	21	(2.24)	119	(2.93)	0.15
	Pain at the injection site	S	8	(0.25)	0	(0)	8	(0.19)	0.12
	Edema at the injection site	Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
	Edema at the injection site	Mo	5	(0.16)	0	(0)	5	(0.12)	0.22
	Redness at the injection site	Mi	28	(0.89)	9	(0.96)	37	(0.91)	0.85
	Redness at the injection site	Mo	7	(0.22)	0	(0)	7	(0.17)	0.14
	Redness at the injection site	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Hematoma at the injection site	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Swelling	Mi	4	(0.12)	2	(0.21)	6	(0.14)	0.55
	Induration at the application site	Mi	11	(0.35)	3	(0.32)	14	(0.34)	0.88
	Inflammation	Mi	13	(0.41)	1	(0.1)	14	(0.34)	0.15
	Nerve injury at the injection site	Mi	0	(0)	2	(0.21)	2	(0.04)	0.009
	Itching at the injection site	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Musculoskeletal and connective tissue disorders	Total	10	(0.32)	0	(0)	10	(0.24)	0.08
		Mi	6	(0.19)	0	(0)	6	(0.14)	0.17
		Mo	4	(0.12)	0	(0)	4	(0.09)	0.27
		S	0	(0)	0	(0)	0	(0)	
	Pain in a limb	Mi	4	(0.12)	0	(0)	4	(0.09)	0.27
	Pain in a limb	Mo	3	(0.09)	0	(0)	3	(0.07)	0.34
	Discomfort in the extremities	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Discomfort in the extremities	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC: System Organ Class; PT: Preferred term; AE: Adverse Event; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S. P-value calculated from comparison of proportions (Z-test)

Supplementary Table 2. Proportion of affected subjects by systemic adverse events of special interest at 7 days post-immunization

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
-----	----	----------	-----	---	----	---	-------	---	---------

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
Subjects			3120		936		4056		
Any AE		Total	596	(19.1)	203	(21.68)	799	(19.69)	0.08
		Mi	496	(15.89)	183	(19.55)	679	(16.74)	0.008
		Mo	139	(4.45)	39	(4.16)	178	(4.38)	0.70
		S	16	(0.51)	2	(0.21)	18	(0.44)	0.22
Supplementary examinations		Total	1	(0.03)	1	(0.1)	2	(0.04)	0.36
		Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
		S	0	(0)	0	(0)	0	(0)	
	High blood pressure elevation	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
Infections and infestations		Total	2	(0.06)	0	(0)	2	(0.04)	0.43
		Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
		S	0	(0)	0	(0)	0	(0)	
	Oral herpes	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Oral herpes	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
Cardiac disorders		Total	3	(0.09)	3	(0.32)	6	(0.14)	0.11
		Mi	2	(0.06)	3	(0.32)	5	(0.12)	0.05
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
		S	0	(0)	0	(0)	0	(0)	
	Chest pain	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Palpitations	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Tachycardia	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Tachycardia	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
Skin and subcutaneous tissue disorders		Total	6	(0.19)	2	(0.21)	8	(0.19)	0.89
		Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
		Mo	1	(0.03)	1	(0.1)	2	(0.04)	0.36
		S	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	Rash	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Excessive sweating	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Excessive sweating	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Skin lesion	Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
	Hives	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Hives	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	Reproductive and breast disorders	Total	3	(0.09)	1	(0.1)	4	(0.09)	0.92
		Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
		S	0	(0)	0	(0)	0	(0)	
	Polymenorrhea	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Polymenorrhea	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	Heavy menstrual bleeding	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Menstrual disorders	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Metabolism and nutrition disorders	Total	0	(0)	1	(0.1)	1	(0.02)	0.07
		Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
		Mo	0	(0)	0	(0)	0	(0)	
		S	0	(0)	0	(0)	0	(0)	
	Decreased appetite	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Ear and labyrinth disorders	Total	2	(0.06)	1	(0.1)	3	(0.07)	0.67
		Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
		Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
		S	0	(0)	0	(0)	0	(0)	
	Vertigo	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Vertigo	Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
	Immune system disorders	Total	2	(0.06)	0	(0)	2	(0.04)	0.43
		Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
		Mo	0	(0)	0	(0)	0	(0)	

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
		S	0	(0)	0	(0)	0	(0)	
	Hypersensitivity	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Nervous system disorders	Total	270	(8.65)	98	(10.47)	368	(9.07)	0.08
		Mi	193	(6.18)	77	(8.22)	270	(6.65)	0.02
		Mo	69	(2.21)	21	(2.24)	90	(2.21)	0.95
		S	10	(0.32)	1	(0.1)	11	(0.27)	0.27
	Headache	Mi	171	(5.48)	72	(7.69)	243	(5.99)	0.01
	Headache	Mo	66	(2.11)	21	(2.24)	87	(2.14)	0.81
	Headache	S	8	(0.25)	0	(0)	8	(0.19)	0.12
	Dizziness	Mi	15	(0.48)	7	(0.74)	22	(0.54)	0.32
	Dizziness	Mo	2	(0.06)	0	(0)	2	(0.04)	0.43
	Migraine	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Paresthesia	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Drowsiness	Mi	11	(0.35)	1	(0.1)	12	(0.29)	0.22
	Drowsiness	Mo	3	(0.09)	0	(0)	3	(0.07)	0.34
	Drowsiness	S	4	(0.12)	1	(0.1)	5	(0.12)	0.87
	Tremor	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Gastrointestinal disorders	Total	62	(1.98)	21	(2.24)	83	(2.04)	0.62
		Mi	47	(1.5)	19	(2.02)	66	(1.62)	0.26
		Mo	15	(0.48)	2	(0.21)	17	(0.41)	0.26
		S	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Diarrhea	Mi	25	(0.8)	10	(1.06)	35	(0.86)	0.43
	Diarrhea	Mo	8	(0.25)	1	(0.1)	9	(0.22)	0.39
	Diarrhea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Abdominal distension	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Abdominal pain	Mi	5	(0.16)	1	(0.1)	6	(0.14)	0.70
	Abdominal pain	Mo	2	(0.06)	0	(0)	2	(0.04)	0.43
	Abdominal pain	S	0	(0)	1	(0.1)	1	(0.02)	0.07

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	Upper abdominal pain	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Constipation	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Nausea	Mi	4	(0.12)	6	(0.64)	10	(0.24)	0.005
	Nausea	Mo	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Odynophagia	Mi	12	(0.38)	4	(0.42)	16	(0.39)	0.85
	Odynophagia	Mo	4	(0.12)	0	(0)	4	(0.09)	0.27
	Vomiting	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
	Vomiting	Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
	Aphthous ulcer	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
General disorders and administration site alterations	Total		255	(8.17)	110	(11.75)	365	(8.99)	0.0008
		Mi	204	(6.53)	99	(10.57)	303	(7.47)	0.000
		Mo	50	(1.6)	14	(1.49)	64	(1.57)	0.81
		S	7	(0.22)	0	(0)	7	(0.17)	0.14
	Asthenia	Mi	21	(0.67)	3	(0.32)	24	(0.59)	0.21
	Asthenia	Mo	2	(0.06)	0	(0)	2	(0.04)	0.43
	Chest pain	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Flu-like illness	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Flu-like illness	Mo	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Influenza-like illness	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Shivering	Mi	8	(0.25)	16	(1.7)	24	(0.59)	0.000
	Shivering	Mo	3	(0.09)	1	(0.1)	4	(0.09)	0.92
	Shivering	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Fatigue	Mi	109	(3.49)	29	(3.09)	138	(3.4)	0.55
	Fatigue	Mo	30	(0.96)	9	(0.96)	39	(0.96)	0.99
	Fatigue	S	6	(0.19)	0	(0)	6	(0.14)	0.17
	Peripheral coldness	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Hyperthermia	Mi	5	(0.16)	3	(0.32)	8	(0.19)	0.33
	Inflammation	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	Discomfort	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Discomfort	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	General discomfort	Mi	19	(0.6)	9	(0.96)	28	(0.69)	0.25
	General discomfort	Mo	4	(0.12)	1	(0.1)	5	(0.12)	0.87
	Chest tightness	Mi	1	(0.03)	1	(0.1)	2	(0.04)	0.36
	Pyrexia	Mi	50	(1.6)	51	(5.44)	101	(2.49)	0.000
	Pyrexia	Mo	14	(0.44)	4	(0.42)	18	(0.44)	0.93
	Pyrexia	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Decreased thirst	Mi	0	(0)	1	(0.1)	1	(0.02)	0.06
	Feeling cold	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
Musculoskeletal and connective tissue disorders		Total	139	(4.45)	51	(5.44)	190	(4.68)	0.20
		Mi	98	(3.14)	43	(4.59)	141	(3.47)	0.03
		Mo	41	(1.31)	8	(0.85)	49	(1.2)	0.25
		S	3	(0.09)	0	(0)	3	(0.07)	0.34
	Arthralgia	Mi	29	(0.92)	21	(2.24)	50	(1.23)	0.001
	Arthralgia	Mo	10	(0.32)	4	(0.42)	14	(0.34)	0.62
	Arthralgia	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Back pain	Mi	5	(0.16)	2	(0.21)	7	(0.17)	0.72
	Back pain	Mo	3	(0.09)	0	(0)	3	(0.07)	0.34
	Ligament sprain	Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
	Muscle spasms	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Myalgia	Mi	68	(2.17)	24	(2.56)	92	(2.26)	0.48
	Myalgia	Mo	31	(0.99)	4	(0.42)	35	(0.86)	0.10
	Myalgia	S	2	(0.06)	0	(0)	2	(0.04)	0.43
	Discomfort in limbs	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Ocular disorders		Total	1	(0.03)	1	(0.1)	2	(0.04)	0.36
		Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
		S	0	(0)	0	(0)	0	(0)	
	Allergic conjunctivitis	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	Photopsia	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Psychiatric disorders	Total	5	(0.16)	3	(0.32)	8	(0.19)	0.33
		Mi	5	(0.16)	3	(0.32)	8	(0.19)	0.33
		Mo	0	(0)	0	(0)	0	(0)	
		S	0	(0)	0	(0)	0	(0)	
	Mood changes	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Confusional state	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Insomnia	Mi	1	(0.03)	2	(0.21)	3	(0.07)	0.07
	Irritability	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
	Respiratory, thoracic and mediastinal disorders	Total	111	(3.55)	24	(2.56)	135	(3.32)	0.13
		Mi	88	(2.82)	23	(2.45)	111	(2.73)	0.55
		Mo	24	(0.76)	3	(0.32)	27	(0.66)	0.13
		S	3	(0.09)	0	(0)	3	(0.07)	0.34
	Asthma	Mi	0	(0)	1	(0.1)	1	(0.02)	0.07
	Nasal congestion	Mi	12	(0.38)	3	(0.32)	15	(0.36)	0.77
	Nasal congestion	Mo	2	(0.06)	0	(0)	2	(0.04)	0.43
	Dyspnea	Mi	2	(0.06)	0	(0)	2	(0.04)	0.43
	Dyspnea	Mo	0	(0)	1	(0.1)	1	(0.02)	0.07
	Dyspnea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Pharyngolaryngeal pain	Mi	9	(0.28)	2	(0.21)	11	(0.27)	0.69
	Pharyngolaryngeal pain	Mo	7	(0.22)	1	(0.1)	8	(0.19)	0.47
	Pharyngolaryngeal pain	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Hiccups	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Allergic rhinitis	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	Rhinorrhea	Mi	61	(1.95)	14	(1.49)	75	(1.84)	0.36
	Rhinorrhea	Mo	15	(0.48)	1	(0.1)	16	(0.39)	0.10

SOC	PT	Severity	AVX	%	AZ	%	Total	%	p-Value
	Rhinorrhea	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Cough	Mi	17	(0.54)	7	(0.74)	24	(0.59)	0.47
	Cough	Mo	6	(0.19)	1	(0.1)	7	(0.17)	0.58
	Cough	S	1	(0.03)	0	(0)	1	(0.02)	0.58
	Productive cough	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
Vascular disorders		Total	5	(0.16)	1	(0.1)	6	(0.14)	0.70
		Mi	4	(0.12)	1	(0.1)	5	(0.12)	0.87
		Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
		S	0	(0)	0	(0)	0	(0)	
	Flushing	Mi	2	(0.06)	1	(0.1)	3	(0.07)	0.67
	Flushing	Mo	1	(0.03)	0	(0)	1	(0.02)	0.58
	Hypertensive crisis	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58
	Hypertension	Mi	1	(0.03)	0	(0)	1	(0.02)	0.58

SOC: System Organ Class; PT: Preferred term; AE: Adverse Event; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S. P-value calculated from comparison of proportions (Z-test).

Supplementary Table 3. Percentage of total, CD4⁺ and CD8⁺ T cells producing IFN- γ in response to fraction 1 of spike protein stimulation

Vacuna	AVX/COVID-12				AZ/ChAdOx-1-S				
	Medición	Basal	Day 14	Day 90	Day 180	Basal	Day 14	Day 90	Day 180
Sujetos	53	53	44	34	50	50	40	33	
	T Lymphocytes								
Mediana	0.082	0.076	0.079	0.05 *	0.087	0.098	0.071	0.036 *	
RIQ	0.059 - 0.134	0.059 - 0.152	0.059 - 0.107	0.027 - 0.083	0.066 - 0.129	0.07 - 0.144	0.049 - 0.093	0.021 - 0.077	
	CD4⁺ T Lymphocytes								
Mediana	0.041	0.051	0.045	0.034	0.05	0.05	0.041	0.0319 *	
RIQ	0.028 - 0.075	0.035 - 0.087	0.029 - 0.062	0.021 - 0.084	0.027 - 0.079	0.033 - 0.075	0.028 - 0.072	0.021 - 0.045	
	CD8⁺ T Lymphocytes								
Mediana	0.015	0.019	0.017	0.017	0.013	0.021 *	0.016	0.014	
RIQ	0.008 - 0.026	0.011 - 0.033	0.011 - 0.033	0.009 - 0.022	0.006 - 0.033	0.01 - 0.057	0.009 - 0.03	0.006 - 0.023	

IQR: Interquartile range p25-p75. p-values: * \leq 0.05 for intra-group comparisons using the Wilcoxon signed-rank test.

* Statistically significant increase compared to baseline values, * Statistically significant decrease compared to baseline values.